MATTHEW P. SMELTZER

University of Memphis, School of Public Health
3825 Desoto Avenue, Robison Hall 222, Memphis, TN 38152
E-mail: msmltzer@memphis.edu
www.memphis.edu/sph/contact/faculty_profiles/smeltzer.php

EDUCATION

PhD	2014	Epidemiology School of Public Health, University of Memphis, Memphis, TN
MStat	2004	Statistics Department of Statistics, University of Florida, Gainesville, FL
BS	2001	Mathematics (cum laude) Harding University, Searcy, AR

TRAINING AND ACCREDITATION

Fellow	2019	Training Institute for Dissemination and Implementation Research in Cancer, National Cancer Institute
PStat	2014	Accredited Professional Statistician, American Statistical Association

APPOINTMENTS

Professor of Epidemiology and Biostatistics (tenured) 2026-
University of Memphis, School of Public Health

Helen and Jabie Hardin Endowed Professor of Public Health 2025-
University of Memphis

University Research Professor 2021-
University of Memphis

Associate Professor of Epidemiology and Biostatistics (tenured) 2020-
University of Memphis, School of Public Health

Assistant Professor (tenure-track), Epidemiology and Biostatistics 2015-2020
University of Memphis, School of Public Health

Director of Epidemiology and Biostatistics, Thoracic Oncology Research Group 2016-
Baptist Cancer Center, Memphis, TN

Member, Graduate Faculty 2015-
University of Memphis Graduate School

Epidemiologist and Biostatistician, Thoracic Oncology Research Group 2015-2016
Baptist Cancer Center, Memphis TN

Lead Senior Biostatistician, Department of Biostatistics 2012-2015
St. Jude Children's Research Hospital, Memphis, TN

Senior Biostatistician, Department of Biostatistics 2009-2012
St. Jude Children's Research Hospital, Memphis, TN

Biostatistical Consultant, Thoracic Oncology Research Group, 2008-2014
University of Tennessee Cancer Institute, Memphis, TN

Biostatistician, Department of Biostatistics 2006-2009
St. Jude Children's Research Hospital, Memphis, TN

Statistical Analyst, Department of Biostatistics 2004-2006
St. Jude Children's Research Hospital, Memphis, TN

ADDITIONAL PROFESSIONAL APPOINTMENTS

Chair 2024-2031
Methodology Committee
IASLC Staging and Prognostic Factors Group
10th Edition UICC/AJCC Tumor, Node, Metastasis (TNM) classification system
for lung cancer, thymic cancer, and mesothelioma.

Board of Directors 2024-
Rescue Lung Society

Chair 2025-2027
IASLC Communications Committee

Member 2025-
Cancer Prevention and Control for the UTHSC Center for Cancer Research

TEACHING AND MENTORING

Professor, University of Memphis 2026-

- Epidemiology in Public Health III (Modern Epidemiology) (PUBH 8174) Fall 2026-
- Doctoral Professional Development Seminar (PUBH 8901) Fall 2026

Associate Professor, University of Memphis 2021-2026

- Epidemiology in Public Health III (Modern Epidemiology) (PUBH 8174) Fall or Spring 2020-2025
- Doctoral Professional Development Seminar (PUBH 8901) Fall 2023-2025
- Analytic and Research Methods in Public Health I (PUBH 3150) Fall 2020-2021, Spring 2022
- Analytic and Research Methods in Public Health II (PUBH 4151) Spring 2021-2023

Assistant Professor, University of Memphis 2015-2020

- Applied Categorical Data Analysis (PUBH 7311/8311) Spring 2016-2017, Fall 2017-2019
- Applied Survival Analysis (PUBH 7309/8309) Fall 2016, Spring 2018-2020
- Biostatistical Methods I (PUBH 7150/8150) Fall 2015
- Special Problems (PUBH 8400) [Bias and Causation] Spring 2020
- Special Problems (PUBH 8400) [Quantitative Bias Analysis] Fall 2017, Fall 2019
- Masters Thesis (PUBH 7996) Spring 2017

Doctoral Dissertation Chair, University of Memphis

- 6 graduated students (1 co-chair)
- 6 current students

Graduate Teaching Assistant, University of Florida, College of Medicine, 2002

- Evidence Based Medicine (PAS 5013) - Graduate Teaching Assistant

Graduate Teaching Assistant, University of Florida, Department of Statistics, 2001-2003

- Introduction to Statistics (STA 2023)- Graduate Teaching Assistant (4 semesters)
- Mathematical Statistics with Computer Applications (STA 4033) - Graduate Teaching Assistant

HONORS AND AWARDS

2026 Distinguished Research Award in Science, Engineering and Mathematics. University of Memphis.

2026 Honorary Head Coach of Memphis Tigers Men's Basketball team (Tigers Ascending to Excellence Award)

2025 Dean's Faculty Research Award, University of Memphis

2025 Helen and Jabie Hardin Endowed Professor of Public Health, University of Memphis

2021 University Research Professorship, University of Memphis

2021 Presidential Plenary at IASLC World Conference on Lung Cancer

2017 IASLC Tsuguo Naruke Lectureship Award

2016 IASLC World Conference on Lung Cancer- Young Investigator Communications Workshop Award

PEER-REVIEW PUBLICATIONS

**Underline indicates student as first author.*

2022-2026

1. Pasquinelli MM, Durney CH, Hill T, Atueyi U, Kovitz K, Abdelhady K, Koshy M, Wang M, Osarogiagbon RU, Mayfield WR, Warner ET, **Smeltzer MP**, Ogbeide O, Feldman J, Potter AL, Jeffrey Yang CF, Kent DA, Chang A, Fintelmann FJ, Sequist LV, Weinberg F. Brief Report: Validation of the Sybil Lung Cancer Risk Prediction Model in a Predominantly Black Screening Cohort. J Thorac Oncol. 2026 Sep 28:106128. doi: 10.1016/j.jtho.2026.106128.PMID: 42805462.

2. Harris KM, Keller MR, Heitzer A, **Smeltzer MP**, Cooper WO, Davis RL, Hankins JS, King AA. Academic Achievement in Eighth Graders with Sickle Cell Disease: Statewide Retrospective Analysis.in press, Pediatrics, 2026.

3. **Smeltzer MP**, Gray JE, Shiller M, Studts JL, Feller-Kopman DJ, Aversano J, Lee P, Stiles BM, Wei B, Alvarez B, Lile A, Kisiel M, Emara R, Kim J, Plotkin E. Assessing current diagnostic, staging, and treatment practices in community and academic centers for individuals with stage IB–IIIA non-small cell lung cancer." Transl Lung Cancer Res. 2026 Apr 30;15(4):91.

4. Plegue M, Latta K, Nuliyalu U, Chua KP, Hellemann G, Kanter J, Clyde C, Palominos JV, Zhou M, Attell BK, Snyder A, Okolo A, Janson IA, Reyes C, Kayle M, Plaxco AP, Wiese AD, **Smeltzer MP**, Dasgupta M, Singh A, Reeves SL. Comparison of State Medicaid Data and the T-MSIS Analytic Files for Analyses of People with Sickle Cell Disease. In press, Public Health Reports, 2026.

5. Kim M, Lamlertthon W, Jo H, Cui Y, Yeon M, Choi HY, Hoadley KA, **Smeltzer MP**, Hayward MC, Wilkerson MD, Makowski L, Hayes DN. RAS signaling in lung adenocarcinoma is defined by lineage context and DUSP4 loss. JCI Insight. 2026 Mar 12:e200912. doi: 10.1172/jci.insight.200912. Epub ahead of print. PMID: 41817586.

6. **Smeltzer MP**, Liao W, Goss J, Qureshi T, Johnson S, Harris A, Dortch K, Fehnel C, Ely S, Ray MA, Osarogiagbon R. Reducing smoking requirements for lung screening to address health disparities in a community cohort. JAMA Network Open. 2025;8(6):e2517149. doi:10.1001

7. **Smeltzer MP**, King JC, Connolly C, Brunson K, Chau M, Chen S, Kerpel-Fronius A, Lantuejoul S, Mohan A, Plaxco A, Roy UB, Santos R, Soo R, Woodard G, Wynes MW, Yatabe Y, Young A, Kelly K. The 2024 International Association for the Study of Lung Cancer (IASLC) Global Survey on Biomarker Testing. J Thorac Oncol. 2025 Dec;20(12):1801-1813. doi: 10.1016/j.jtho.2025.07.114. Epub 2025 Jul 22. PMID: 40706709.

8. Mazumder H, Gain EP, Shimul MH, Farah F, Alam N, Mou X, Mzayek F, Jia C, Smeltzer MP, Zhang H, Chang HH, Davis RL, Fu JS, Kovesdy CP, Hossain MM, Naser AM. Ambient Temperature and Risk of Renal Colic: A Systematic Review and Meta-analysis. Kidney Med. 2025 Nov 7;8(1):101179. doi: 10.1016/j.xkme.2025.101179. PMID: 41531667; PMCID: PMC12794254.

9. Mukhopadhyay A, **Smeltzer MP**, Dudley J, Badawy SM, Mathias JG, Plaxco AP, Ray MA, Wiese AD, Stevens WI, Gurney JG, Nwosu C, Porter JS, Klesges LM, Hankins JS, Cooper WO. Hydroxyurea utilization among individuals with sickle cell disease in Tennessee: a pooled analysis of claims data. Front Pharmacol. 2025 Dec 19;16:1693126. doi: 10.3389/fphar.2025.1693126. PMID: 41487491; PMCID: PMC12757755.

10. Pimenta K, Madondo E, Mukhopadhyay A, Patel J, Muhit S, Mzayek F, Bartelli D, **Smeltzer M**, Zhang H. Association between weight-adjusted waist index and cardiovascular disease: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2025 Sep 26;16:1644035. doi: 10.3389/fendo.2025.1644035. PMID: 41079192; PMCID: PMC12511945.

11. Heitzer AM, Ray MA, Wiese A, Dudley J, King AA, Hankins JS, Cooper WO, ****Smeltzer MP**, **Davis R (**co-senior authors). Statewide Academic Performance of High School Students with Sickle Cell Disease. Pediatric Blood and Cancer, 2025, 2025 Oct;72(10):e31947. doi: 10.1002/pbc.31947. Epub 2025 Aug 1. PMID: 40751324; PMCID: PMC12461487.

12. Kayle M, Zhou M, Attell BK, Valle J, Reeves SL, Peng HK, **Smeltzer MP**, Mukhopadhyay A, Amosun T, Sergison J, Snyder AB. Pregnancy and Disease-Related Morbidity Among Medicaid Enrollees with Sickle Cell Disease. In press. Pediatric Blood and Cancer 2025.

13. Wogksch MD, Ware ME, Onerup A, O'Neil ST, Nolan VG, **Smeltzer MP**, Mzayek F, Mulrooney DA, Ehrhardt MJ, Dixon SB, Rhea IB, Srivastava DK, Armstrong GT, Hudson MM, Ness KK. Associations between Cardiopulmonary Fitness and Cardiovascular Events in Survivors of Childhood Cancer: A Report from the St. Jude Lifetime Cohort. Med Sci Sports Exerc. 2025 Jul 1. doi: 10.1249/MSS.0000000000003802.

14. Naidoo J, Niroula A, Uprety D, **Smeltzer MP**, Geissen N, Osarogiagbon R, Mino-Kenudson M, Yatabe Y, Higgins K, Desai A, Reckamp KL, Lin J, Liu S, Hegi-Johnson F, Seetharamu N, Harpole D, Mazotti J, Edelman M, IASLC Communications Committee. 50 years of Progress in Non-Small Cell Lung Cancer: A New Fellow's Guide in the Clinic. J Thorac Oncol. 2025 Jul 3:S1556-0864(25)00819-6. doi: 10.1016/j.jtho.2025.06.028.

15. Liao W, Ray MA, Patel A, Roma J, Marshall H, Fehnel C, Goss J, Ogbeide O, Mehrotra A, Lammers P, Tonkin K, Bishop A**, Smeltzer MP**, Osarogiagbon RU. Barriers to Lung Cancer Screening in a Multi-Disciplinary

Thoracic Oncology Program Cohort: Effects of an Incidental Pulmonary Nodule Program. J Thorac Oncol. 2025 Jan 30:S1556-0864(25)00057-7.

16. **Smeltzer MP**, Akinbobola OA, Ray MA, Fehnel C, Saulsberry A, Dortch KR, Pimenta K, Matthews AT, Osarogiagbon RU. Prevalence of Epidermal Growth Factor Receptor and Programmed Death-Ligand 1 testing in a population-based lung cancer surgical resection cohort from 2018-2022. Cancer Epidemiol Biomarkers Prev. 2024 Aug 1;33(8):1098-1106.

17. Plaxco AP, Kmet J, **Smeltzer MP**, Jiang Y, Taylor M, Nolan VG. Comparative 60-day effectiveness of bivalent versus monovalent mRNA vaccines in Shelby County: a population-level analysis. Ther Adv Vaccines Immunother. 2024 Sep 19;12:25151355241278852.

18. Mukhopadhyay A, Haque Mondol M, Rahman M, Unicomb L, Khan R, Mazumder H, Nahian Ferdous M, Pickering EV, Makris KC, Caban-Martinez AJ, Ahmed F, Shamsudduha M, Mzayek F, Jia C, Zhang H, Musah A, Fleming LE, **Smeltzer MP**, Chang HH, Jefferies JL, Kovesdy CP, Mou X, Mohd Naser A. The direct and urinary electrolyte-mediated effects of ambient temperature on population blood pressure: A causal mediation analysis. Environ Int. 2024 Dec 13;195:109208. doi: 10.1016/j.envint.2024.109208. Epub ahead of print. PMID: 39705978.

19. Lee YS, Sprong ME, Shrestha J, **Smeltzer MP**, Hollender H. Trajectory Analysis for Identifying Classes of Attention Deficit Hyperactivity Disorder (ADHD) in Children of the United States. Clin Pract Epidemiol Ment Health. 2024 May 21;20:e17450179298863.

20. Akinbobola O, Liao W, Ray MA, Fehnel C, Goss J, Qureshi T, Saulsberry A, Dortch K, **Smeltzer MP**, Osarogiagbon RU. Outcomes of Resected Lung Cancer Diagnosed Through Screening and Incidental Pulmonary Nodule Programs in a Mississippi Delta Cohort. JTO Clin Res Rep. 2024 May 16;5(8):100684. doi: 10.1016/j.jtocrr.2024.100684. PMID: 39157675; PMCID: PMC11327436.

21. Attell BK, Plaxco AP, Zhou M, Valle J, Reeves SL, Patel PN, Latta K**, Smeltzer MP**, Snyder AB. Emergency department utilization before and during the COVID-19 pandemic among individuals with sickle cell disease. BMC Emerg Med. 2024 Jul 29;24(1):134.

22. Howell K, Kayle M, **Smeltzer MP**, Nolan VG, Mathias JG, Nelson MN, Anderson S, Porter JS, Shah N, Hankins JS. Gaps during Pediatric to Adult Care Transfer Escalate Acute Resource Utilization in Sickle Cell Disease. Blood Adv. 2024 May 29:bloodadvances.2023011268. doi: 10.1182/bloodadvances.2023011268.

23. Kayle M, Blewer AL, Pan W, Rothman JA, Polick CS, Rivenbark J, Fisher E, Reyes C, Strouse JJ, Weeks S, Desai JR, Snyder AB, Zhou M, Sutaria A, Valle J, Horiuchi SS, Sontag MK, Miller JI, Singh A, Dasgupta M, Janson IA, Galadanci N, Reeves SL, Latta K, Hurden I, Cromartie SJ, Plaxco AP, Mukhopadhyay A**, Smeltzer MP**, Hulihan M. Birth Prevalence of Sickle Cell Disease and County-Level Social Vulnerability - Sickle Cell Data Collection Program, 11 States, 2016-2020. MMWR Morb Mortal Wkly Rep. 2024 Mar 28;73(12):248-254. doi: 10.15585/mmwr.mm7312a1. PMID: 38547025; PMCID: PMC10986820.

24. Ogu UO, Mukhopadhyay A, Patel K, Nelson MN, Strahan KS, Wu L, **Smeltzer MP**, Ataga KI. Hydroxyurea at escalated dose versus fixed low-dose hydroxyurea in adults with sickle cell disease Eur J Haematol. 2024 Mar;112(3):466-474. doi: 10.1111/ejh.14138.

25. Plaxco AP, Hankins JS, Davis RL, Dudley J, Young AJ, Mukhopadyay A, Carroll YM, Aguinaga MDP, Takemoto CM, Nolan VG, Ray MA, Wiese A, Amosun TA, Cooper WO**, Smeltzer MP**. Descriptive Epidemiology of Sickle Cell Disease in Tennessee: Population-based Estimates from 2008 to 2019. Front. Hematol. 2:1277548.doi: 10.3389/frhem.2023.

26. Nwosu C, Khan H, Masese R, Nocek JM, Gollan S, Varughese T, Bourne S, Clesca C, Jacobs SR, Baumann A, Klesges LM, Shah N, Hankins JS, **Smeltzer MP**. Recruitment Strategies in the Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization Study (meSH): Multicenter Survey Study. JMIR Form Res. 2024 Apr 16;8:e48767. doi: 10.2196/48767. PMID: 38625729; PMCID: PMC11061784.

27. **Smeltzer MP**, Reeves S, Cooper WO, Attell BK, Strouse JJ, Takemoto C, Kanter J, Latta K, Plaxco A, Davis RL, Hatch D, Reyes C, Dombkowski K, Snyder A, Paulukonis S, Singh A, Kayle M. Common Data Model for Sickle Cell Disease Surveillance: Considerations and Implications. JAMIA Open. 2023 May 27;6(2):ooad036. doi: 10.1093/jamiaopen/ooad036.

28. Liao W, Fehnel C, Goss J, Shepherd CJ, Qureshi T, Matthews AT, Ray MA, Faris NR, Pinsky PF, **Smeltzer MP**, Osarogiagbon RU. Incidentally-Detected Lung Cancer in Persons Too Young or Too Old for Lung Cancer Screening in a Mississippi Delta Cohort. J Thorac Oncol. 2024 Apr;19(4):589-600. doi: 10.1016/j.jtho.2023.11.015. Epub 2023 Nov 19. PMID: 37984678.

29. Plaxco AP, Kmet JM, Nolan VG, Taylor MA**, Smeltzer MP**. Association Between mRNA Vaccination and Infection From SARS-CoV-2 During the Delta and Omicron BA.1 Waves: A Population-level Analysis . AJPM Focus. 2023 Sep 29;2(4):100150. doi: 10.1016/j.focus.2023.100150. PMID: 37941824; PMCID: PMC10630621.

30. Liao W, Ray M, Fehnel C, Gross J, Shepherd CJ, Patel A, Qureshi T, Caro F, Roma J, Derrick A, Matthews AT, Faris NR, **Smeltzer MP**, Osarogiagbon RU. Program-Based Lung Cancer Care: A Prospective Observational Tumor Registry Linkage Study. JTO Clin Res Rep. 2023 Dec 26;5(2):100629.

31. Reeves SL, Plegue M, Patel PN, Paulukonis ST, Horiuchi SS, Zhou M, Attell BK, Pace BS, Snyder AB, Plaxco AP, Mukhopadhyay A, **Smeltzer MP**, Ellimootil CS, Hulihan M. Assessing Patterns of Telehealth Use among People with Sickle Cell Disease Enrolled in Medicaid During the Start of the COVID-19 Pandemic. Telemed J E Health. 2024 Apr 11. doi: 10.1089/tmj.2023.0422. PMID: 38603584

32. Osarogiagbon RU, Ray MA, Fehnel C, Akinbobola O, Saulsberry A, Dortch K, Faris NR, Matthews AT, **Smeltzer MP**, Spencer D; MS-QSR Consortium. Two Interventions on Pathologic Nodal Staging in a Population-Based Lung Cancer Resection Cohort. Ann Thorac Surg. 2024 Mar;117(3):576-584. doi: 10.1016/j.athoracsur.2023.08.026.

33. Pizzo A, Porter JS, Carroll Y, Burcheri A, **Smeltzer MP**, Beestrum M, Nwosu C, Badawy SM, Hankins JS, Klesges LM, Alberts NM. Provider prescription of hydroxyurea in youth and adults with sickle cell disease: A review of prescription barriers and facilitators Br J Haematol. 2023 Dec;203(5):712-721. doi: 10.1111/bjh.19099.

34. Paulukonis ST, Snyder A, **Smeltzer MP**, Sutaria AN, Hurden I, Latta K, Vichinsky SE, Reeves SL. COVID-19 Infection and Outcomes in Newborn Screening Cohorts of Sickle Cell Trait and Sickle Cell Disease in Michigan and Georgia. J Pediatr Hematol Oncol. 2023 May 1;45(4):174-180. doi: 10.1097/MPH.0000000000002671.

35. Ray MA, Akinbobola O, Fehnel C, Saulsberry A, Dortch K, Wolf B, Valaulikar G, Patel HD, Ng T, Robbins T, **Smeltzer MP**, Faris NR, Osarogiagbon RU; Mid-South Quality of Surgical Resection (MS-QSR) Consortium. Surgeon Quality and Patient Survival After Resection for Non-Small-Cell Lung Cancer. J Clin Oncol. 2023 Jul 10;41(20):3616-3628. doi: 10.1200/JCO.22.01971

36. Shao H, Faris NR, Ward KD, Chen W, McHugh L, **Smeltzer M,** Ray MA, Osarogiagbon RU. Lung Cancer Patients' and Caregivers' Satisfaction With Multidisciplinary Versus Serial Care in a Community Healthcare Setting: A Prospective Comparative-Effectiveness Cohort Study. Clin Lung Cancer. 2023 Nov;24(7):e267-e274. doi: 10.1016/j.cllc.2023.06.006.

37. Elsherif, L Kanthakumar P, Afolabi J, Stratton AF, Ogu U, Nelson M, Mukhopadhyay A, **Smeltzer MP**, Adebiyi A, Ataga KI Urinary Angiotensinogen is Associated with Albuminuria in Adults with Sickle Cell Anemia. Br J Haematol. 2023 Aug;202(3):669-673. doi: 10.1111/bjh.18862. Epub 2023 May 15. PMID: 37189288.

38. Akinbobola O, Ray MA, Fehnel C, Saulsberry A, Dortch K, **Smeltzer MP**, Faris NR, Osarogiagbon RU. Institution-Level Evolution of Lung Cancer Resection Quality with Implementation of a Lymph Node Specimen Collection Kit. J Thorac Oncol. 2023 Jul;18(7):858-868. doi: 10.1016/j.jtho.2023.03.002. Epub 2023 Mar 15. PMID: 36931504; PMCID: PMC10505555.

39. Osarogiagbon RU, Liao W, Faris NR, Fehnel C, Goss J, Shepherd CJ, Qureshi T, Matthews AT, **Smeltzer MP**, Pinsky PF. Lung Cancer Risk in Persons Undergoing Screening or Guideline-Concordant Monitoring of Lung Nodules in the Mississippi Delta. JAMA Netw Open. 2023 Feb 1;6(2):e230787. doi: 10.1001/jamanetworkopen.2023.0787. PMID: 36848089; PMCID: PMC9972195.

40. **Smeltzer MP**, Ray MA, Faris NR, Meadows-Taylor MB, Rugless F, Berryman C, Jackson B, Fehnel C, Pacheco A, McHugh L, Robbins ET, Ward KD, Klesges LM, Osarogiagbon RU. Prospective Comparative Effectiveness Trial of Multidisciplinary Lung Cancer Care Within a Community-Based Health Care System. JCO Oncol Pract. 2023. PMID: 35609221 Clinical Trial.

41. **Smeltzer MP**, Liao W, Faris NR, Fehnel C, Lane JG, Shepherd CJ, Ramos R, Qureshi T, Mukhopadhyay A, Ray MA, Osarogiagbon RU. Potential Impact of Criteria Modifications on Race and Sex Disparities in Eligibility for Lung Cancer Screening. J Thorac Oncol. 2023 Feb;18(2):158-168. doi: 10.1016/j.jtho.2022.09.220. Epub 2022 Oct 5. PMID: 36208717.

42. Wogksch MD, Finch ER, Nolan VG, **Smeltzer MP**, Mzayek F, Goodenough CG, Pui CH, Inaba H, Mulrooney DA, Kaste SC, Brinkman TM, Lanctot JQ, Srivastava DK, Jefferies JL, Armstrong GT, Robison LL, Hudson MM, Ness KK. Energy cost of walking in obese survivors of acute lymphoblastic leukemia: A report from the St. Jude Lifetime Cohort. Front Pediatr. 2022 Oct 28;10:976012. doi: 10.3389/fped.2022.976012. PMID: 36389386; PMCID: PMC9650430.

43. Plaxco AP, Kmet JM, Nolan VG, Taylor MA, **Smeltzer MP.** Real-World Association Between mRNA Vaccination and Infection From the Omicron Strain of SARS-CoV-2: A Population-Level Analysis. AJPM Focus 2022, Volume 1, Issue 1. Doi: 10.1016/j.focus.2022.100010

44. **Smeltzer MP**, Ray MA. Statistical Considerations for Outcomes in Clinical Research: A Review of Common Data Types and Methodology. Experimental Biology and Medicine. 2022 May;247(9):734-742. doi: 10.1177/15353702221085710.

45. **Smeltzer MP**, Scagliotti GV, Wakelee HA, Mitsudomi T, Roy UB, Clark RC, Arndt R, Pruett CD, Kelly KL, Ujhazy P, Johnson ML, Eralp Y, Barrios CH, Barlesi F, Hirsch FR, Bunn PA. International Association for the Study of Lung Cancer (IASLC) Study of the Impact of COVID-19 on International Lung Cancer Clinical Trials. Journal Thoracic Oncology, J Thorac Oncol. 2022 May;17(5):651-660. doi: 10.1016/j.jtho.2022.01.017. Epub 2022 Feb 17.PMID: 35183774.

46. Osarogiagbon RU, Liao W, Faris NR, Meadows-Taylor M, Fehnel C, Lane J, Williams SC, Patel AA, Akinbobola OA, Pacheco A, Epperson A, Luttrell J, McCoy D, McHugh L, Signore R, Bishop AM, Tonkin K, Optican R, Wright J, Robbins T, Ray MA, **Smeltzer MP**. Lung Cancer in Persons Participating in Screening, Lung Nodule Program and Neither: A Prospective Observational Study of the Detecting Early Lung Cancer (DELUGE) in the Mississippi Delta cohort. J Clin Oncol. 2022 Jul 1;40(19):2094-2105. doi: 10.1200/JCO.21.02496. Epub 2022 Mar 8.PMID: 35258994

47. Meadows-Taylor M, Faris NR, **Smeltzer MP**, Ray MA, Fehnel C, Akinbobola OA, Ariganjoye F, Patel A, Pacheco A, Mehrotra A, Fox R, Optican R, Tonkin K, Machin J, Wright J, Robbins E, Osarogiagbon R. The Relative Survival Impact of Guideline-Concordant Clinical Staging and Stage-Appropriate Treatment of

Potentially Curable Non-Small Cell Lung Cancer. Chest. 2022 Jul;162(1):242-255. doi: 10.1016/j.chest.2022.01.046. Epub 2022 Feb 3.PMID: 35122751

48. Temkin SM, **Smeltzer MP**, Dawkins M, Boehmer LM, Senter L, Black D, Blank SV, Yemelyanova A, Magliocco AM, Finkel M, Moore T, Thaker PH. Improving the Quality of Care for Patients With Advanced Epithelial Ovarian Cancer: Program Components, Implementation Barriers, and Recommendations. Cancer. 2022 Feb 15;128(4):654-664. doi: 10.1002/cncr.34023. Epub 2021 Nov 17.PMID: 34787913

2021 and earlier

49. Mathias JG, Nolan VG, Klesges LM, Badawy SM, Cooper WO, Hankins JS, **Smeltzer MP**. Hydroxyurea utilization following transitions of care among young adults with sickle cell disease enrolled in Tennessee Medicaid. JAMA Netw Open. 2021 Oct 1;4(10):e2128971. doi: 10.1001/jamanetworkopen.2021.28971.PMID: 34643722

50. **Smeltzer MP**, Howell K, Marsha Treadwell M, Liliana Preiss L, King A, Glassberg J, Paula Tanabe P, Badawy SM, DiMartino L, Gibson R, Kanter J, Klesges LM, Hankins JS, Sickle Cell Disease Implementation Consortium. Barriers to evidence-based care for sickle cell disease in the US: Results from the Sickle Cell Disease Implementation Consortium Provider Needs Assessment. BMJ Open. 2021 Nov 17;11(11):e050880. doi: 10.1136/bmjopen-2021-050880.PMID: 34789492

51. **Smeltzer MP**, Hodges TP, Whartenby J, Hankins JS, Davis R, Cooper WO. Three Wishes for Sickle Cell Disease: Results from a multi-stakeholder vision-casting project in Tennessee. Clinical Health Promotion. 2021 Sep. 16;11(2):e21014. https://doi.org/10.29102/clinhp.21014

52. Wang W, Freeman M, Hamilton L, Carroll Y, Kang G, Moen J, **Smeltzer MP**, Schreiber J, Heitzer AM, Estepp J, Aygun B. Developmental screening of three-year-old children with sickle cell disease compared to controls. Br J Haematol. 2021 Nov;195(4):621-628. doi: 10.1111/bjh.17780. Epub 2021 Aug 15.PMID: 34396511

53. Chang JG, Regen RB, Peravali R, Harlan SS, **Smeltzer MP**, Kink RJ. Intranasal Fentanyl and Midazolam Use in Children 3 Years of Age and Younger in the Emergency Department. J Emerg Med. 2021 Dec;61(6):731-739. doi: 10.1016/j.jemermed.2021.09.006.PMID: 34920841

54. **Smeltzer MP**, Lee YS, Faris NR, Fehnel C, Akinbobola O, Meadows-Taylor M, Spencer D, Sales E, Okun S, Giampapa C, Anga A, Pacheco A, Ray M, Osarogiagbon RU. Trends in Accuracy and Comprehensiveness of Pathology Reports for Resected Non-small Cell Lung Cancer (NSCLC) in a High Mortality Area of the United States. J Thorac Oncol. 2021 Oct;16(10):1663-1671. doi: 10.1016/j.jtho.2021.06.027. Epub 2021 Jul 16.PMID: 34280563

55. Ray M, Faris N, Fehnel C, Derrick A, **Smeltzer M**, Meadows-Taylor M, Arigandoye F, Pacheco A, Optican R, Tonkin K, Wright J, Fox R, Callahan T, Robbins E, Walsh W, Lammers P, Satpute S, Osarogiagbon RU. Survival Impact of an Enhanced Multidisciplinary Thoracic Oncology Conference in a Regionals Community Healthcare System. JTO Clin Res Rep. 2021 Jul 3;2(8):100203. doi: 10.1016/j.jtocrr.2021.100203. eCollection 2021 Aug.PMID: 34590046

56. **Smeltzer MP**, Faris N, Fehnel C, Akinbobola O, Saulsberry A, Meadows-Taylor M, Pacheco A, Ray M, Osarogiagbon RU. Impact of a Lymph Node Specimen Collection Kit on the Distribution and Survival Implications of the Proposed Revised Lung Cancer Residual Disease Classification: a Propensity-Matched Analysis. JTO Clin Res Rep. 2021 Mar 9;2(4):100161. doi: 10.1016/j.jtocrr.2021.100161. eCollection 2021 Apr.PMID: 34590011

57. Elsherif L, Scott LC, Wichlan D, Jones SK, Mathias JG, Shen JH, **Smeltzer MP**, Ataga KI. Hydroxyurea therapy decreases coagulation and endothelial activation in sickle cell disease: a Longitudinal Study. Br J Haematol. 2021 Aug;194(3):e71-e73. doi: 10.1111/bjh.17650. Epub 2021 Jul 6.PMID: 34231209

58. **Smeltzer MP**, Boehmer L, Kramar A, Asfeldt T, Faris N, Amorosi C, Ray M, Nolan V, Oyer R, Lathan C, Osarogiagbon R. An Optimal Care Coordination Model for Medicaid Patients With Lung Cancer: Results From the Beta Model Testing Phase of a Multisite Initiative in the United States. Oncology Issues, 2021, 36:3, 80-94, DOI: 10.1080/10463356.2021.1901553

59. Ray MA, Fehnel C, Akinbobola O, Faris NR, Meadows-Taylor M , **Smeltzer MP**, Osarogiagbon RU. Comparative Effectiveness of a Lymph Node Collection kit Versus 'Heightened Awareness' on Lung Cancer Surgery Quality and Outcomes. J Thorac Oncol. 2021 May;16(5):774-783. doi: 10.1016/j.jtho.2021.01.1618. Epub 2021 Feb 12.PMID: 33588112

60. Thaker P, **Smeltzer MP**, Dawkins M, Senter-Jamieson L, Blank SV, Black D, Finkel M, Yemelyanova A, Boehmer LM, Temkin S. Improving the Quality of Care for Persons with Advanced Epithelial Ovarian Cancer. Oncology Issues,2021, 36:2, 36-48, DOI: 10.1080/10463356.2021.1879583

61. Oyer RA, Lathan CS, **Smeltzer MP**, Kramar A, Boehmer L, Asfeldt T. An Optimal Care Coordination Model for Medicaid Patients With Lung Cancer: Finalization of the Model and Implications for Clinical Practice in the U.S. Oncology Issues, 2021, 36:4, 70-78, DOI: 10.1080/10463356.2021.1930441

62. Osarogiagbon RU, **Smeltzer MP**, Faris NR, Ray MA, Fehnel C, Ojeabulu P, Akinbobola O, Meadows-Taylor M, McHugh LM, Halal AM, Levy P, Sachdev V, Talton R, Wiggins L, Shu X, Shyr Y, Robbins ET, Klesges LM. Outcomes Following Use of a Lymph Node Collection Kit for Lung Cancer Surgery: A Pragmatic, Population-Based, Multi-Institutional, Staggered Implementation Study. J Thorac Oncol. 2021 Apr;16(4):630-642. doi: 10.1016/j.jtho.2020.12.025. Epub 2021 Feb 16.PMID: 33607311

63. **Smeltzer MP**, Wynes MW, Lantuejoul S, Soo R, Ramalingam SS, VarellaGarcia M, Taylor MM, Richeimer K, Wood K, Howell KE, Dalurzo ML, Felip E, Hollenbeck G, Kerr K, Kim ES, Mathias C, Pacheco J, Postmus P, Powell C, Tsuboi M, Wistuba II, Wakelee HA, Belani CP, Scagliotti GV, Hirsch FR, The International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung Cancer, J Thorac Oncol. 2020: 15(9):1434–1448.

64. Ray MR, **Smeltzer MP**, Faris N, Osarogiagbon R. Survival After Mediastinal Node Dissection, Systematic Sampling, or Neither for Early Stage NSCLC. J Thorac Oncol. 2020: Jun 20;S1556-0864(20)30479-2.

65. Mathias JG, Nolan V, Meadows-Taylor M, Robinson LA, Howell K, Gurney J, Hankins J, Wang W, Estepp J, **Smeltzer MP**. A Meta-analysis of Toxicities Related to Hydroxycarbamide Dosing Strategies. *eJHaem*. 2020; 1: 235– 238. https://doi.org/10.1002/jha2.7

66. Ray MR, Faris N, Derrick A, **Smeltzer MP**, Osarogiagbon R. Rurality, Stage-Stratified Use of Treatment Modalities and Survival of Non-small Cell Lung Cancer. Chest. 2020 Aug;158(2):787-796.

67. Kanter J, Gibson R, Lawrence RH, **Smeltzer MP**, Pugh NL, Glassberg G, Masese RV, King AA, Calhoun C, Hankins JS, Treadwell M. Perceptions of US Adolescents and Adults with Sickle Cell Disease on their Quality of Care. JAMA Netw Open. 2020 May 1;3(5):e206016.

68. Minden-Birkenmaier BA, Meadows MB, Cherukuri K, **Smeltzer MP**, Smith RA, Radic MZ, Bowlin GL. Manuka Honey Modulates the Release Profile of a dHL-60 Neutrophil Model under Anti-Inflammatory Stimulation. J Tissue Viability. 2020 May;29(2):91-99. doi: 10.1016/j.jtv.2020.03.005.

69. Alberts NM, Badawy SM, Hodges J, Estepp J, Nwosu C, Khan H, **Smeltzer MP**, Homayuni R, Norell S, Klesges L, Porter JS, Hankins JS. Development of the Mobile App "InCharge Health" to Improve Adherence to Hydroxyurea in Sickle Cell Disease: A User-centered Design Approach. JMIR Mhealth Uhealth. 2020 May 8;8(5):e14884.

70. Osarogiagbon RU, Faris NR, Stevens W, Fehnel C, Houston-Harris C, Ojeabulu P, Akinbobola O, Lee YS, Ray MA, **Smeltzer MP**. Beyond Margin Status: Population-Based Validation of the Proposed IASLC Residual Tumor Classification Re-categorization. J Thorac Oncol. 2020 Mar;15(3):371-382.

71. Williams H, Howell CR, Chemaitilly W, Wilson CL, Karol SE, Nolan VG, **Smeltzer MP**, Green DM, Ehrhardt MJ, Mulrooney DA, Pui CH, Hudson MM, Robison LL, Ness KK. Diabetes among adult survivors of childhood acute lymphoblastic leukemia: A report from the St. Jude Lifetime Cohort Study. Cancer. 2020 Feb 15;126(4):870-878. doi: 10.1002/cncr.32596.

72. Thomas K, Voros B, Meadows-Taylor M, **Smeltzer MP**, Griffin R, Boudreaux JP, Thiagarajan R, Woltering E, Ramirez R. Outcomes of capecitabine and temozolomide (CAPTEM) in advanced neuroendocrine neoplasms (NENs). Cancers (Basel). 2020 Jan 14;12(1). pii: E206. doi: 10.3390/cancers12010206.

73. Osarogiagbon R, Lee YS, Faris NR, Ray M, Ojeabulu P, **Smeltzer MP**. Invasive Mediastinal Staging for Resected Non-Small Cell Lung Cancer in a Population-Based Cohort. J Thorac Cardiovasc Surg. 2019 May 2. pii: S0022-5223(19)30968-7.

74. Minden-Birkenmaier BA, Meadows MB, Cherukuri K, **Smeltzer MP**, Smith RA, Radic MZ, Bowlin GL. The Effect of Manuka Honey on dHL-60 Cytokine, Chemokine, and Matrix-Degrading Enzyme Release under Inflammatory Conditions. Med One. 2019;4(2). pii: e190005. doi: 10.20900/mo.20190005.

75. Yates AM, Joshi VM, Aygun B, Moen J, Kang G, **Smeltzer MP**, Govindaswamy D, Dowdy J, Cotton A, Ware RE, Hankins JS. Elevated Tricuspid Regurgitation Velocity in Congenital Hemolytic Anemias: Prevalence and Laboratory Correlates. Pediatr Blood Cancer. 2019 Jul;66(7):e27717.

76. Shayeb AM, **Smeltzer MP**, Kaste SC, Brown A, Estepp JE, Nottage K. Vaso-occlusive crisis as a predictor of symptomatic avascular necrosis in children with sickle cell disease, Pediatr Blood Cancer, 2018 Dec;65(12):e27435. doi: 10.1002/pbc.27435.

77. **Smeltzer MP**, Faris NR, Ray MA, Fehnel C, Houston-Harris C, Ojeabulu P, Akinbobola O, Lee YS, Meadows M, Signore S, Wiggins L, Talton D, Owen E, Deese LE, Eubanks R, Wolf BA, Levy P, Robbins ET, Osarogiagbon RU. Survival before and after direct surgical quality feedback in a population-based lung cancer cohort. Ann Thorac Surg. 2018 Dec 27. pii: S0003-4975(18)31859-9.

78. Hankins JS, Estepp JE, Hodges JR, Villavicencio MA, Robison LL, Weiss MJ, Kang G, Schreiber JE, Porter JS, Kaste SC, Saving KL, Bryant PC, Deyo JE, Nottage KA, King AA, Brandow AM, Lebensburger JD, Adesina O, Chou ST, Zemel BS, **Smeltzer MP**, Wang WC, Gurney JG. Sickle Cell Clinical Research and Intervention Program (SCCRIP): A Lifespan Cohort Study for Sickle Cell Disease Progression from Pediatric into Adulthood. Pediatr Blood Cancer. 2018 May 24:e27228. doi: 10.1002/pbc.27228.

79. **Smeltzer MP**, Rugless F, Jackson B, Foust C, Faris NR, Ray M, Meadows M, Patel A, Roark K, Kedia S, DeBon M, Crossley F, Oliver G, McHugh L, Hastings W, Osborne O, Osborne J, Ill T, Ill M, Jones W, Lee HK, Signore RS, Fox R, Li J, Robbins ET, Ward KD, Klesges LM, Osarogiagbon R. Pragmatic Trial of a Multidisciplinary Lung Cancer Care Model in a Community Healthcare Setting: Study Design, Implementation Evaluation, and Baseline Clinical Results. Transl Lung Cancer Res. 2018 Feb;7(1):88-102. doi: 10.21037/tlcr.2018.01.02.

80. Ray MA, Faris NR, **Smeltzer MP**, Fehnel C, Houston-Harris C, Levy P, Wiggins L, Sachdev V, Robbins ET, Spencer D, Osarogiagbon RU. Effectiveness of Implemented Interventions on Pathologic Nodal Staging of Non-Small Cell Lung Cancer, Ann Thorac Surg. 2018 Jul;106(1):228-234.

81. Bi W, Li Y, **Smeltzer MP**, Gao G, Zhao S, Lin X, Kang G. STEPS: An Efficient Prospective Likelihood Approach to Genetic Variant Association analyses of Secondary Traits in Extreme Phenotype Sequencing, Biostatistics. 2018 Jul 11. doi: 10.1093/biostatistics/kxy030.

82. **Smeltzer MP**, Faris NR, Ray MA, Osarogiagbon RU. Association of pathologic nodal staging quality with survival among patients with non–small cell lung cancer after resection with curative intent. JAMA Oncol. 2018: 4(1)1-8. Published September 28, 2017. doi:10.1001/jamaoncol.2017.2993

83. Fetz AE, Neeli I, Buddington KK, Read RW, **Smeltzer MP**, Radic MZ, Bowlin GL. Localized Delivery of Cl-Amidine From Electrospun Polydioxanone Templates to Regulate Acute Neutrophil NETosis: A Preliminary

Evaluation of the PAD4 Inhibitor for Tissue Engineering. Front. Pharmacol. 2018; 9:289. doi: 10.3389/fphar.2018.00289

84. Nolan VG, Anderson SM, **Smeltzer MP**, Porter JS, Carroll YM, Brooks IM, Elmagboul N, Gurney JG, Hankins JS. Pediatric to Adult Care Co-location Transitional Model for Youth with Sickle Cell Disease. Am J Hematol. 2018 Jan;93(1):E30-E32.

85. Estepp JH, **Smeltzer MP**, Kang G, Li C, Wang WC, Abrams C, Aygun B, Ware RE, Nottage K, Hankins JS. A Clinically Meaningful Fetal Hemoglobin Threshold for Children with Sickle Cell Anemia During Hydroxyurea Therapy. Am J Hematol. 2017 Dec;92(12):1333-1339.

86. Estepp JH, **Smeltzer MP**, Kang G, Howard SC, Reiss UM. Safe Use of Low Molecular Weight Heparin in Pediatric Acute Lymphoblastic Leukemia and Lymphoma Around Lumbar Punctures. J Pediatr Hematol Oncol. 2017 Nov;39(8):596-601.

87. Lin CC, **Smeltzer MP**, Jemal A, Osarogiagbon R. Risk-Adjusted Margin Positivity Rate as a Surgical Quality Metric for Non-Small-Cell Lung Cancer. Ann Thorac Surg 2017;104:1161–70.

88. **Smeltzer MP,** Lin CC, Kong FM , Jemal A, and Osarogiagbon RU. Survival Impact of Post-Operative Therapy Modalities According to Margin Status in Non-Small Cell Lung Cancer Patients in the United States. J Thorac Cardiovasc Surg. 2017 Apr 4. pii: S0022-5223(17)30604-9.

89. Osarogiagbon R, Ray M, Faris N, **Smeltzer MP**, Fehnel C, Houston-Harris C, Signore R, McHugh L, Levy P, Wiggins L, Sachdev V, Robbins E. Prognostic Value of National Comprehensive Cancer Network Lung Cancer Resection Quality Parameters. Ann Thorac Surg. 2017 May;103(5):1557-1565.

90. Faris N, **Smeltzer MP**, Lu F, Fehnel C, Chakraborty N, Houston-Harris C, Robbins E, Signore R, McHugh L, Wolf B, Wiggins L, Levy P, Sachdev V, Osarogiagbon R. Evolution in the Surgical Care of Non-Small Cell Lung Cancer (NSCLC) Patients in the Mid-South Quality of Surgical Resection (MS-QSR) Cohort. Sem. Card. Vasc. Surg., Spring 2017, Volume 29, Issue 1, Pages 91–101.

91. Loeffler RB, McCarville MB, Wilson A, **Smeltzer M**, Krafft AJ, Song R, Hankins J, Hillenbrand CM. Can Multi-slice or Navigator-gated R2*-MRI Replace Single-slice Breath-hold Acquisition for Hepatic Iron Quantification? Pediatr Radiol. 2017 Jan;47(1):46-54.

92. Sachdev JC, Snider JN, Allen JW, Schwartzberg LS, Young RR, Javed AY, **Smeltzer MP**, Yunus F, Verrier CS, Jahanzeb M. Neoadjuvant Weekly nab-Paclitaxel Plus Carboplatin Followed by Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently to Chemotherapy for Palpable and Operable Triple-Negative Invasive Breast Cancer. Journal of Cancer and Allied Specialties. 2016; 2(1).

93. Nottage K, Ware RE, Aygun B, **Smeltzer MP**, Kang G, Moen J, Wang W, Hankins J, Helton K,. Hydroxycarbamide Treatment and Brain MRI/MRA Findings in Children with Sickle Cell Anaemia. Br J Haematol. 2016 Oct;175(2):331-338.

94. Li Q, Zhan P, Dongmei Y, Lv Y, Krupnick AS, Passaro A, Brunelli A, **Smeltzer MP**, Osarogiagbon RU, Song Y. Prognostic value of lymph node ratio in patients with pathological N1 non-small cell lung cancer: a systematic review with meta-analysis. Transl Lung Cancer Res. 2016 Jun;5(3):258-64.

95. **Smeltzer MP**, Faris N, Yu X, Spencer D, Berry A, Sales E, Finch-Cruz C, Osarogiagbon RO. The Survival Impact of Missed Lymph Node Metastasis in Surgically Resected Non-Small Cell Lung Cancer. Ann Thorac Surg. 2016 Aug;102(2):448-53.

96. Nottage KA, Hankins JS, James D, Richardson J, Christensen R, Kang G, **Smeltzer MP**, Cancio M, Wang WC, Anghelescu D. Addressing Challenges of Clinical Trials in Acute Pain: ThePain Management of Vaso-occlusive Crisis in Sickle CellDisease Study. ClinTrials. 2016 Aug;13(4):409-16.

97. **Smeltzer MP**, Nolan VG, Yu X, Nottage KA, Davis B, Yang Y, Wang WC, Gurney JG, Hankins JS. The Birth Prevalence of Sickle Cell Trait and Sickle Cell Disease in Shelby County, TN. Pediatr Blood Cancer. 2016 Jun;63(6):1054-9.

98. Osarogiagbon RU, Lin CC, **Smeltzer MP**, Jemal A. Prevalence, prognostic implications and survival modulators of incompletely resected non-small-cell lung cancer in the US National Cancer Data Base. Journal of Thoracic Oncology, J Thorac Oncol. 2016 Jan;11(1):e5-e16. PMID: 26762752

99. Pestina T, Hargrove PW, Zhao HF, **Smeltzer MP**, Weiss MJ, Wilber A, Persons DA. Amelioration of murine sickle cell disease by nonablative conditioning and γ-globin gene-corrected bone marrow cells. Mol Ther Methods Clin Dev. 2015;2:15045.

100. Hankins JS, McCarville MB, Rankine-Mullings A, Reid ME, Lobo C, Moura P, Ali S, Soares D, Aldred K, Jay DW, Aygun B, Bennett J, Kang G, Goldsmith JC, **Smeltzer MP**, Boyett JM, Ware RE. Prevention of Conversion to Abnormal TCD with Hydroxyurea in Sickle Cell Anemia: A Phase II International Randomized Clinical Trial. American Journal of Hematology, 2015 90(12): 1099–1105.

101. **Smeltzer MP**, Nolan VG, Yu X, Nottage KA, Wang WC, Hankins JS, Gurney JG. The Effects of Distance from an Urban Sickle Cell Center on Routine Healthcare Management and Rates of Hospitalization. Hemoglobin, 2015 Sep 15:1-6. [Epub ahead of print] PMID: 26372097

102. Yu X, Klesges L, **Smeltzer MP,** Osarogiagbon R. Measuring improvement in populations: implementing and evaluating successful change in lung cancer care. Trans. Lung Cancer Research, 2015; 4(4): 373-384.

103. Cancio MI, Helton KJ,Schreiber JE, **Smeltzer MP**, Kang G, Wang WC. Silent cerebral infarcts in very young children with sickle cell anaemia are associated with a higher risk of stroke. British Journal of Haematology, 2015 Oct;171(1):120-9.

104. Porter JS, Matthews CS, Carroll YM, Anderson SM, **Smeltzer MP**, Hankins JS. Genetic education and sickle cell disease: Feasibility and efficacy of a program tailored to adolescents. Journal of Pediatric Hematology and Oncology; 36 (7), 572-577, 2014

105. Hankins JS, Aygun B, Nottage K, Thornburg C, **Smeltzer MP**, Ware RE, Wang WC. From Infancy to Adolescence: Fifteen Years of Continuous Treatment with Hydroxyurea in Sickle Cell Anemia. Medicine, 93(28):e215, 2014.

106. Estepp JH, Winter B, Johnson M, **Smeltzer MP**, Howard SC, Hankins JS. Improved hydroxyurea effect with the use of text messaging in children with sickle cell anemia. Pediatric Blood and Cancer; 61(11):2031-36, 2014.

107. Nottage KA, Ware RE, Winter B, **Smeltzer M**, Wang WC, Hankins JS, Dertinger SD, Shulkin B, and Aygun B. Predictors of splenic function preservation in children with sickle cell anemia treated with hydroxyurea. Eur J Haematol. 2014; 93(5):377-83

108. Bettini M, Jennifer L. Blanchfield JL, Castellaw A, Zhang Q, Nakayama M, **Smeltzer MP**, Zhang H, Hogquist KA, Evavold BD, Vignali DA. TCR affinity and tolerance mechanisms converge to shape T cell diabetogenic potential. J Immunol. 2014 Jul 15;193(2):571-9.

109. Helton, KG; Reddick, W; Paydar, A; Zandieh, A, Dave, R; **Smeltzer, MP**; Wu, S; Hankins, J; Aygun, B; Ogg, R Comparing segmented ASL perfusion of vascular territories using manual vs. semi-automated techniques in children with sickle cell anemia. Journal of Magnetic Resonance Imaging. 2015, 41:439–446.

110. Hankins, J; **Smeltzer, M**; Wu, S; Aygun, B; Clarke, D. Assessment of Sleep-Related Disorders in Children with Sickle Cell Disease. Hemoglobin 2014;38(4):244-51.

111. Osarogiagbon RU; Wang, CG; Miller LE; Adair CA; **Smeltzer M**; Yu X; Berry A. Size and histologic characteristics of lymph node material retrieved from remnant tissue after routine pathologic examination of lung cancer resection specimens. Ann. of Diagn. Pathol. 2014 Jun;18(3):136-9.

112. Nottage KA, Hankins JS, **Smeltzer M**, Mzayek F, Wang WC, Aygun B, Gurney JG. Hydroxyurea use and hospitalization trends in a comprehensive pediatric sickle cell program. *PloS one.* 2013;8(8):e72077.

113. Sheehan VA, Hansbury EN, **Smeltzer MP**, Fortner G, McCarville MB, Aygun B. Transcranial Doppler velocity and brain MRI/MRA changes in children with sickle cell anemia on chronic transfusions to prevent primary stroke. *Pediatric blood & cancer.* Sep 2013;60(9):1499-1502.

114. Osarogiagbon RU, Ramirez RA, Wang CG, Miller LE, **Smeltzer M**, Sareen S, Javed AY, Robbins SG, Khandekar A, Wolf BA, Gibson J, Spencer D, Robbins ET. Dual intervention to improve pathologic staging of resectable lung cancer. *The Annals of thoracic surgery.* Dec 2013;96(6):1975-1981.

115. Despotovic JM, McGann PT, **Smeltzer M**, Aygun B, Ware RE. RHD zygosity predicts degree of platelet response to anti-D immune globulin treatment in children with immune thrombocytopenia. *Pediatric blood & cancer.* Sep 2013;60(9):E106-108.

116. Guy CS, Vignali KM, Temirov J, Bettini ML, Overacre AE, **Smeltzer M**, Zhang H, Huppa JB, Tsai YH, Lobry C, Xie J, Dempsey PJ, Crawford HC, Aifantis I, Davis MM, Vignali DA. Distinct TCR signaling pathways drive proliferation and cytokine production in T cells. *Nature immunology.* Mar 2013;14(3):262-270.

117. Estepp JH, **Smeltzer MP**, Wang WC, Hoehn ME, Hankins JS, Aygun B. Protection from sickle cell retinopathy is associated with elevated HbF levels and hydroxycarbamide use in children. *British journal of haematology.* May 2013;161(3):402-405.

118. Cook CM, **Smeltzer MP**, Mortier NA, Kirk SE, Despotovic JM, Ware RE, Hankins JS. The clinical and laboratory spectrum of Hb C [beta6(A3)Glu-->Lys, GAG>AAG] disease. *Hemoglobin.* 2013;37(1):16-25.

119. Yates AM, Dedeken L, **Smeltzer MP**, Lebensburger JD, Wang WC, Robitaille N. Hydroxyurea treatment of children with hemoglobin SC disease. *Pediatric blood & cancer.* Feb 2013;60(2):323-325.

120. Aygun B, Mortier NA, **Smeltzer MP**, Shulkin BL, Hankins JS, Ware RE. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia. *American journal of hematology.* Feb 2013;88(2):116-119.

121. Finch P, Stocks RM, **Smeltzer MP**, Kimble A, Schoumacher R, Hankins JS. Effects of adenotonsillectomy on polysomnographic parameters in children with sickle cell disease. *Pediatric blood & cancer.* Jul 2013;60(7):E26-28.

122. Nottage K, Gurney JG, **Smeltzer M**, Castellanos M, Hudson MM, Hankins JS. Trends in transfusion burden among long-term survivors of childhood hematological malignancies. *Leukemia & lymphoma.* Aug 2013;54(8):1719-1723.

123. Anghelescu DL, Burgoyne LL, Faughnan LG, Hankins GM, **Smeltzer MP**, Pui CH. Prospective randomized crossover evaluation of three anesthetic regimens for painful procedures in children with cancer. *The Journal of pediatrics.* Jan 2013;162(1):137-141.

124. Hankins JS, Osarogiagbon R, Adams-Graves P, McHugh L, Steele V, **Smeltzer MP**, Anderson SM. A transition pilot program for adolescents with sickle cell disease. *Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners.* Nov-Dec 2012;26(6):e45-49.

125. Cejda KR, **Smeltzer MP**, Hansbury EN, McCarville ME, Helton KJ, Hankins JS. The impact of preparation and support procedures for children with sickle cell disease undergoing MRI. *Pediatric radiology.* Oct 2012;42(10):1223-1228.

126. Williams-Hooker R, Olivi S, **Smeltzer MP**, Wang W. Health-Related Quality of Life is Associated with Hemoglobin Level in Children with Sickle Cell Anemia. *J Blood Disorders Transf.* 2012;3(4).

127. McCullers JA, Williams BF, Wu S, **Smeltzer MP**, Williams BG, Hayden RT, Howard SC, Pui CH, Hughes WT. Healthcare-Associated Infections at a Children's Cancer Hospital, 1983-2008. *Journal of the Pediatric Infectious Diseases Society.* Mar 2012;1(1):26-34.

128. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, Tangsombatvisit S, Grosso JF, Netto G, **Smeltzer MP**, Chaux A, Utz PJ, Workman CJ, Pardoll DM, Korman AJ, Drake CG, Vignali DA. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. *Cancer research.* Feb 15 2012;72(4):917-927.

129. Estepp JH, **Smeltzer M**, Reiss UM. The impact of quality and duration of enoxaparin therapy on recurrent venous thrombosis in children. *Pediatric blood & cancer.* Jul 15 2012;59(1):105-109.

130. Ware RE, Despotovic JM, Mortier NA, Flanagan JM, He J, **Smeltzer MP**, Kimble AC, Aygun B, Wu S, Howard T, Sparreboom A. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. *Blood.* Nov 3 2011;118(18):4985-4991.

131. Walker AL, Steward S, Howard TA, Mortier N, **Smeltzer M**, Wang YD, Ware RE. Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemia. *Blood.* Nov 17 2011;118(20):5664-5670.

132. Zou P, Helton KJ, **Smeltzer M**, Li CS, Conklin HM, Gajjar A, Wang WC, Ware RE, Ogg RJ. Hemodynamic responses to visual stimulation in children with sickle cell anemia. *Brain imaging and behavior.* Dec 2011;5(4):295-306.

133. Aygun B, Mortier NA, **Smeltzer MP**, Hankins JS, Ware RE. Glomerular hyperfiltration and albuminuria in children with sickle cell anemia. *Pediatric nephrology.* Aug 2011;26(8):1285-1290.

134. Aygun B, Parker J, Freeman MB, Stephens AL, **Smeltzer MP**, Wu S, Hankins JS, Wang WC. Neurocognitive screening with the Brigance preschool screen-II in 3-year-old children with sickle cell disease. *Pediatric blood & cancer.* Apr 2011;56(4):620-624.

135. Fowler KT, Williams R, Mitchell CO, Levy MC, Pope LF, **Smeltzer MP**, Wang WC. Dietary water and sodium intake of children and adolescents with sickle cell anemia. *Journal of pediatric hematology/oncology.* Jul 2010;32(5):350-353.

136. McCarville MB, Hillenbrand CM, Loeffler RB, **Smeltzer MP**, Song R, Li CS, Hankins JS. Comparison of whole liver and small region-of-interest measurements of MRI liver R2* in children with iron overload. *Pediatric radiology.* Aug 2010;40(8):1360-1367.

137. Hankins JS, **Smeltzer MP**, McCarville MB, Aygun B, Hillenbrand CM, Ware RE, Onciu M. Patterns of liver iron accumulation in patients with sickle cell disease and thalassemia with iron overload. *European journal of haematology.* Jul 2010;85(1):51-57.

138. Hankins JS, McCarville MB, Hillenbrand CM, Loeffler RB, Ware RE, Song R, **Smeltzer MP**, Joshi V. Ventricular diastolic dysfunction in sickle cell anemia is common but not associated with myocardial iron deposition. *Pediatric blood & cancer.* Sep 2010;55(3):495-500.

139. Flanagan JM, Howard TA, Mortier N, Avlasevich SL, **Smeltzer MP**, Wu S, Dertinger SD, Ware RE. Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. *Mutation research.* Apr 30 2010;698(1-2):38-42.

140. Hankins JS, McCarville MB, Loeffler RB, **Smeltzer MP**, Onciu M, Hoffer FA, Li CS, Wang WC, Ware RE, Hillenbrand CM. R2* magnetic resonance imaging of the liver in patients with iron overload. *Blood.* May 14 2009;113(20):4853-4855.

141. McCarville MB, Monu N, **Smeltzer MP**, Li CS, Laningham FH, Morris EB, Shulkin BL. PET-CT of the normal spinal cord in children. *Academic radiology.* Jul 2009;16(7):881-885.

142. Karplus G, McCarville MB, **Smeltzer MP**, Spyridis G, Rao BN, Davidoff A, Li CS, Shochat S. Should contralateral exploratory thoracotomy be advocated for children with osteosarcoma and early unilateral pulmonary metastases? *Journal of pediatric surgery.* Apr 2009;44(4):665-671.

143. Helton KJ, Paydar A, Glass J, Weirich EM, Hankins J, Li CS, **Smeltzer MP**, Wang WC, Ware RE, Ogg RJ. Arterial spin-labeled perfusion combined with segmentation techniques to evaluate cerebral blood flow in white and gray matter of children with sickle cell anemia. Pediatric blood & cancer. Jan 2009;52(1):85-91.

144. Mahindroo N, Connelly MC, Punchihewa C, Kimura H, **Smeltzer MP**, Wu S, Fujii N. Structure-activity relationships and cancer-cell selective toxicity of novel inhibitors of glioma-associated oncogene homologue 1 (Gli1) mediated transcription. Journal of medicinal chemistry. Jul 23 2009;52(14):4277-4287.

145. McCarville MB, Goodin GS, Fortner G, Li CS, **Smeltzer MP**, Adams R, Wang W. Evaluation of a comprehensive transcranial doppler screening program for children with sickle cell anemia. Pediatric blood & cancer. Apr 2008;50(4):818-821.

146. Burton AR, Vincent E, Arnold PY, Lennon GP, **Smeltzer M**, Li CS, Haskins K, Hutton J, Tisch RM, Sercarz EE, Santamaria P, Workman CJ, Vignali DA. On the pathogenicity of autoantigen-specific T-cell receptors. Diabetes. May 2008;57(5):1321-1330.

147. Hankins JS, Fortner GL, McCarville MB, **Smeltzer MP**, Wang WC, Li CS, Ware RE. The natural history of conditional transcranial Doppler flow velocities in children with sickle cell anaemia. British journal of haematology. Jul 2008;142(1):94-99.

148. McCarville MB, Whittle SB, Goodin GS, Li CS, **Smeltzer MP**, Hale GA, Kaufman RA. Clinical and CT features of benign pneumatosis intestinalis in pediatric hematopoietic stem cell transplant and oncology patients. *Pediatric radiology.* Oct 2008;38(10):1074-1083.

149. Morris EB, Shelso J, **Smeltzer MP**, Thomas NA, Karimova EJ, Li CS, Merchant T, Gajjar A, Kaste SC. The use of bone age for bone mineral density interpretation in a cohort of pediatric brain tumor patients. *Pediatric radiology.* Dec 2008;38(12):1285-1292.

150. Razzouk BI, Rose SR, Hongeng S, Wallace D, **Smeltzer MP**, Zacher M, Pui CH, Hudson MM. Obesity in survivors of childhood acute lymphoblastic leukemia and lymphoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology.* Apr 1 2007;25(10):1183-1189.

151. Burgoyne LL, **Smeltzer MP**, Pereiras LA, Norris AL, De Armendi AJ. How well do pediatric anesthesiologists agree when assigning ASA physical status classifications to their patients? *Paediatric anaesthesia.* Oct 2007;17(10):956-962.

EDITORIALS AND LETTERS

1. **Smeltzer MP**, Osarogiagbon RU. Multifaceted Approach Needed for Early Lung Cancer Detection. IASLC Lung Cancer News, February 07, 2023.

2. **Smeltzer MP**, Laio W, Osarogiagbon RU. In Response:Letter to the editor: Re “Smeltzer MP, Liao W, Faris NR, et al. Potential Impact of Criteria Modifications on Race and Sex Disparities in Eligibility for Lung Cancer Screening. J Thorac Oncol 2023; 2: 158-168” J Thorac Oncol. 2023 Jun;18(6):e58-e59. doi: 10.1016/j.jtho.2023.03.017. PMID: 37210182.

3. **Smeltzer MP**, Ray MA, Faris NR, Osarogiagbon RU. Genie out of the bottle: Is there a role for gene-gene interactions in early detection of lung cancer? J Thorac Oncol. 2022 Aug;17(8):946-948. doi: 10.1016/j.jtho.2022.05.012. PMID: 35931422.

4. Akinbobola O, Ray MA, **Smeltzer MP**, Osarogiagbon RU. In Response. Re: Taichiro Goto 'Kit use may not be key to improved prognosis'; response to "Akinbobola O, Ray MA, Fehnel C, et al. Institution-Level Evolution of Lung Cancer Resection Quality With Implementation of a Lymph Node Specimen Collection Kit." J Thorac Oncol. 2023 Aug;18(8):e80-e81. doi: 10.1016/j.jtho.2023.05.01.

5. Roy UB, Baird AM, Ciupek A, Fox J, Manley E Jr, Norris K, Scagliotti GV, Wakelee HA, Mitsudomi T, Clark RC, Arndt R, Hirsch FR, Bunn PA, **Smeltzer MP**. Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials: Why It Matters to People With Lung Cancer. JTO Clin Res Rep. 2022 Feb;3(2):100269. doi: 10.1016/j.jtocrr.2021.100269. PMID: 34961851

6. Oyer RO*, **Smeltzer MP***, Kramar A, Boehmer L, Lathan C. Equity-Driven Approaches to Optimizing Cancer Care Coordination and Reducing Care Delivery Disparities in Underserved Patient Populations in the U.S. JCO Oncol Pract. 2021 May;17(5):215-218. doi: 10.1200/OP.20.00895. Epub 2021 Apr 9.PMID: 33974823 *equal contribution

7. **Smeltzer MP**, Wynes MW, Bunn B, Wakelee HA, Belani CP. Improving Molecular Testing in Lung Cancer: What We Learned From the IASLC Global Survey. IASLC Lung Cancer News, Jan 13, 2021.

8. Osarogiagbon RU, Ray MA, Faris NR, Smeltzer MP. Response to: "Lymph Node Dissection for Non-Small-Cell Lung Cancer at Whose Discretion?". J Thorac Oncol. 2021 May;16(5):e36-e37. doi: 10.1016/j.jtho.2021.01.1627. PMID: 33896579.

9. **Smeltzer MP**, Osarogiagbon RU. Out of the darkness, into light: the scientific rigor of lung cancer clinical trials in the age of enlightenment. J Thorac Oncol. 2020, Jul;15(7):1110-1112.

10. Osarogiagbon RU, Ray MA, Faris NR, **Smeltzer MP**. Response to Clinical Thoughts on Mediastinal Node Management in Early-Stage Lung Cancer. J Thorac Oncol. 2020 Nov;15(11):e185-e186. doi: 10.1016/j.jtho.2020.08.028. Epub 2020 Oct 23. PMID: 33148414.

11. Osarogiagbon RU, **Smeltzer MP**, Faris N, Rami-Porta R, Goldstraw P, Asamura H. Comment on the Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016 Oct;11(10):1612-4.

PEER-REVIEW CONSORTIUM PUBLICATIONS

1. Abrams CM, Davila N, Badawy SM, Kepper MM, Gibson RW, King AA, Gordeuk VR, Nwosu C, Li S, Glassberg JA, Klesges LM, Shah N, Brambilla D, Hankins JS; Sickle Cell Disease Implementation Consortium. User Perceptions of a Multilevel mHealth Intervention to Boost Adherence to Hydroxyurea in Sickle Cell Disease. Pediatr Blood Cancer. 2025 Jul;72(7):e31746. doi: 10.1002/pbc.31746. Epub 2025 May 5. PMID: 40325557.

2. Longoria JN, Howell KE, Porter JS, Treadwell M, King AA, Gordeuk V, Shah N, Abrams CM, McCuskee S, Gollan S, Hankins JS, Heitzer AM; Sickle Cell Disease Implementation Consortium. Depression, sleep and pain affect instrumental activities of daily living through cognitive functioning in adults with sickle cell disease: A report from the Sickle Cell Disease Implementation Consortium. Br J Haematol. 2025 Mar;206(3):944-953. doi: 10.1111/bjh.19881. Epub 2024 Nov 20. PMID: 39564946; PMCID: PMC12784454.

3. Mendez GG, Nocek JM, Brambilla DJ, Jacobs S, Cole O, Kanter J, Glassberg J, Saving KL, Melvin CL, Gibson RW, Treadwell M, Jackson GL, King AA, Gordeuk VR, Kroner B, Hsu LL; **Sickle Cell Disease Implementation Consortium**. Social determinants of health and treatment center affiliation: analysis from the sickle cell disease implementation consortium registry. BMC Health Serv Res. 2024 Mar 6;24(1):291. doi: 10.1186/s12913-024-10717-6. PMID: 38448911; PMCID: PMC10916176.

4. Harris KM, Preiss L, Varughese T, Bauer A, Calhoun CL, Treadwell M, Masese R, Hankins JS, Hussain FA, Glassberg J, Melvin CL, Gibson R, King AA; **Sickle Cell Disease Implementation Consortium**. Examining Mental Health, Education, Employment, and Pain in Sickle Cell Disease. JAMA Netw Open. 2023 May 1;6(5):e2314070. doi: 10.1001/jamanetworkopen.2023.14070. PMID: 37200033; PMCID: PMC10196879.

5. Ibemere SO, Oyedeji CI, Preiss L, Van Althuis LE, Hankins JS, Azul M, Burns EN, Glassberg J, Hagar W, Hussain F, King A, Melvin C, Myers J, Snyder A, Shah N, Tanabe P; **Sickle Cell Disease Implementation Consortium**. Characterising the prevalence of overweight and obese status among adults with sickle cell disease. Br J Haematol. 2023 Mar;200(5):633-642. doi: 10.1111/bjh.18548. Epub 2022 Nov 16. PMID: 36382420; PMCID: PMC9957798.

6. Hankins JS, Potter MB, Fernandez ME, Melvin C, DiMartino L, Jacobs SR, Bosworth HB, King AA, Simon J, Glassberg JA, Kutlar A, Gordeuk VR, Shah N, Baumann AA, Klesges LM; **Sickle Cell Disease Implementation Consortium**. Evaluating the implementation of a multi-level mHealth study to improve hydroxyurea utilization in sickle cell disease. Front Health Serv. 2023 Jan 20;2:1024541. doi: 10.3389/frhs.2022.1024541. PMID: 36925803; PMCID: PMC10012741.

7. Lamont AE, Hsu LL, Jacobs S, Gibson R, Treadwell M, Chen Y, Lottenberg R, Axelrod K, Varughese T, Melvin C, Smith S, Chukwudozie IB, Kanter J; **Sickle Cell Disease Implementation Consortium**. What does it mean to be affiliated with care?: Delphi consensus on the definition of "unaffiliation" and "specialist" in sickle cell disease. PLoS One. 2022 Nov 11;17(11):e0272204. doi: 10.1371/journal.pone.0272204. PMID: 36367870; PMCID: PMC9651581.

8. Badawy SM, DiMartino L, Brambilla D, Klesges L, Baumann A, Burns E, DeMartino T, Jacobs S, Khan H, Nwosu C, Shah N, Hankins JS; **Sickle Cell Disease Implementation Consortium**. Impact of the COVID-19 Pandemic on the Implementation of Mobile Health to Improve the Uptake of Hydroxyurea in Patients With Sickle Cell Disease: Mixed Methods Study. JMIR Form Res. 2022 Oct 14;6(10):e41415. doi: 10.2196/41415. PMID: 36240004; PMCID: PMC9578525.

9. Treadwell MJ, Mushiana S, Badawy SM, Preiss L, King AA, Kroner B, Chen Y, Glassberg J, Gordeuk V, Shah N, Snyder A, Wun T; **Sickle Cell Disease Implementation Consortium** (SCDIC). An evaluation of patient-reported outcomes in sickle cell disease within a conceptual model. Qual Life Res. 2022 Sep;31(9):2681-2694. doi: 10.1007/s11136-022-03132-z. Epub 2022 Apr 21. PMID: 35445915; PMCID: PMC9356962.

10. Kroner BL, Hankins JS, Pugh N, Kutlar A, King AA, Shah NR, Kanter J, Glassberg J, Treadwell M, Gordeuk VR; **Sickle Cell Disease Implementation Consortium**. Pregnancy outcomes with hydroxyurea use in women with sickle cell disease. Am J Hematol. 2022 May;97(5):603-612. doi: 10.1002/ajh.26495. Epub 2022 Feb 17. PMID: 35142007; PMCID: PMC8986611.

11. DiMartino LD, Baumann AA, Hsu LL, Kanter J, Gordeuk VR, Glassberg J, Treadwell MJ, Melvin CL, Telfair J, Klesges LM, King A, Wun T, Shah N, Gibson RW, Hankins JS; **Sickle Cell Disease Implementation Consortium**. The sickle cell disease implementation consortium: Translating evidence-based guidelines into practice for sickle cell disease. Am J Hematol. 2018 Dec;93(12):E391-E395. doi: 10.1002/ajh.25282.

12. Baumann AA, Belle SH, James A, King AA; **Sickle Cell Disease Implementation Consortium**. Specifying sickle cell disease interventions: a study protocol of the Sickle Cell Disease Implementation Consortium (SCDIC). BMC Health Serv Res. 2018 Jun 27;18(1):500. doi: 10.1186/s12913-018-3297-1.

13. Knisely MR, Pugh N, Kroner B, Masese R, Gordeuk V, King AA, Smith SM, Gurney JG, Adams R, Wun T, Snyder A, Glassberg J, Shah N, Treadwell M; **Sickle Cell Disease Implementation Consortium.** Patient-reported outcomes in sickle cell disease and association with clinical and psychosocial factors: Report from the sickle cell disease implementation consortium. Am J Hematol. 2020 Sep;95(9):1066-1074. doi: 10.1002/ajh.25880. Epub 2020 Jun 29. PMID: 32449965.

14. Glassberg JA, Linton EA, Burson K, Hendershot T, Telfair J, Kanter J, Gordeuk VR, King AA, Melvin CL, Shah N, Hankins JS, Epié AY, Richardson LD; **Sickle Cell Disease Implementation Consortium**. Publication of data collection forms from NHLBI funded sickle cell disease implementation consortium (SCDIC) registry. Orphanet J Rare Dis. 2020 Jul 7;15(1):178. doi: 10.1186/s13023-020-01457-x. PMID: 32635939; PMCID: PMC7341606.

15. Masese RV, DeMartino T, Bonnabeau E, Burns EN, Preiss L, Varughese T, Nocek JM, Lasley P, Chen Y, Davila C, Nwosu C, Scott S, Bowman L, Gordon L, Clesca C, Peters-Lawrence M, Melvin C, Shah N, Tanabe P; **SCD Implementation Consortium**. Effective Recruitment Strategies for a Sickle Cell Patient Registry Across Sites from the Sickle Cell Disease Implementation Consortium (SCDIC). J Immigr Minor Health. 2020 Oct 9. doi: 10.1007/s10903-020-01102-6. Epub ahead of print. PMID: 33034793.

16. Masese RV, Bulgin D, Knisely MR, Preiss L, Stevenson E, Hankins JS, Treadwell MJ, King AA, Gordeuk VR, Kanter J, Gibson R, Glassberg JA, Tanabe P, Shah N; **Sickle Cell Disease Implementation Consortium**. Sex-based differences in the manifestations and complications of sickle cell disease: Report from the Sickle Cell Disease Implementation Consortium. PLoS One. 2021 Oct 29;16(10):e0258638. doi: 10.1371/journal.pone.0258638. PMID: 34714833; PMCID: PMC8555833.

17. Linton EA, Goodin DA, Hankins JS, Kanter J, Preiss L, Simon J, Souffront K, Tanabe P, Gibson R, Hsu LL, King A, Richardsona LD, Glassberg JA; **Sickle Cell Disease Implementation Consortium.** A Survey-Based Needs Assessment of Barriers to Optimal Sickle Cell Disease Care in the Emergency Department. Ann Emerg Med. 2020 Sep;76(3S):S64-S72. doi: 10.1016/j.annemergmed.2020.08.013. PMID: 32928465; PMCID: PMC7511000.

18. Hankins JS, Shah N, DiMartino L, Brambilla D, Fernandez ME, Gibson RW, Gordeuk VR, Lottenberg R, Kutlar A, Melvin C, Simon J, Wun T, Treadwell M, Calhoun C, Baumann A, Potter MB, Klesges L, Bosworth H; **Sickle Cell Disease Implementation Consortium**. Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation Study. JMIR Res Protoc. 2020 Jul 14;9(7):e16319. doi: 10.2196/16319. PMID: 32442144; PMCID: PMC7388044.

Pubmed:
http://www.ncbi.nlm.nih.gov/sites/myncbi/matthew.smeltzer.1/bibliograpahy/50372746/public/?sort=date&direction=descending

ORCID: 0000-0003-1366-9267 https://orcid.org/0000-0003-1366-9267



Invited Lectures and Conference Leadership (2020-)

IASLC Committee Grand Rounds. Updates from IASLC Communications Committee. October 28, 2026.

Global Communication: Getting the Message Across for Patients and Clinicians in an Age of Ceaseless Noise.(Session Chair). 2026 World Conference on Lung Cancer. Seoul, Korea. September 12, 2026.

IASLC Staging and Prognostic Factors Group World Staging Day. Updates from the Methodology Committee. Seoul, Korea. September 11, 2026.

Analytic Methods for Clinical Research: Study Designs, Threats to Validity, and Statistical Power. International Association for the Study of Lung Cancer Academy. March 19, 2026

Data Collection Systems for Multi-Site Collaborations. Multinational Lung Cancer Control Program Africa Technical Workshop. Hoedspruit, Mpumalanga, South Africa. February 10, 2026

Harnessing Observational Data: Methodological Approaches for Single and Multi-Institution Research Using a Common Data Model. BMS Foundation 2025 Africa Grantee Summitt. Johannesburg, South Africa, October 22, 2025.

Expanding eligibility criteria for lung cancer screening (Moderator)
Rescue Lung Society Conference. October 24-25, 2025. Boston, MA.

Power and Sample Size for your Clinical Trial
2025 World Conference on Lung Cancer September 6, 2025.
Barcelona, Spain

Debates, Discussions & Didactics on Science Communications in 2025 (Session Chair)
2025 World Conference on Lung Cancer September 6, 2025.
Barcelona, Spain

Epidemiology for Surgeons 101

2025 Women in Thoracic Surgery Conference, November 6, 2025*
Fernandina Beach, FL

The 2024 International Association for the Study of Lung Cancer (IASLC) Global Survey on Biomarker Testing: Results from Asia
Best of Asia Conference on Lung Cancer
December 2024, Online.

The disproportionate impact of housing discrimination on individuals living with sickle cell disease.
Centers for Disease Control and Prevention.
SCDC Summit, October 28, 2024
Atlanta, GA

Assessing the Cancer Risk of Lung Nodules by Proteomic or Gene Expression Panels
Masters of Thoracic Oncology Conference, November 23, 2024
Lake Tahoe, CA

Demystifying the Data: Creating Clarity from the Complex
2024 World Conference on Lung Cancer September 7, 2024.
San Diego, CA

Updates on biomarker testing patterns for individuals with lung cancer.
Computational Masters in Genomics Fall 2024 Symposium – St. Jude CompBio & UTHSC Sept 18, 2024
Memphis, TN

Updates from the Sickle Cell Data collection Program: Multi-state Approach and Current Progress
ALSTATE: Improving Care for Sickle Cell Disease through Surveillance in Alabama
Lifespan Comprehensive Sickle Cell Center at UAB Feb 22, 2024, Birmingham, AL

Sickle Cell Data Collection Program: Overview, Approach, and Progress
NHLBI 2023 Annual Sickle Cell Disease Research Meeting. August 16, 2023
National Institutes of Health, Bethesda, MD.

Simplifying Stats and Methods in Scientific Communication
2023 World Conference on Lung Cancer September 8, 2023.
Singapore, Singapore.

Biomarker testing and quality care for individuals with lung cancer.
University of Tennessee Health Sciences Center Cancer Seminar. Oct 24, 2023
Memphis, TN

Promoting Your Research through Traditional and Social Media Networks
2022 World Conference on Lung Cancer August 6, 2022.
Vienna, Austria

Updates from the IASLC Survey on the Impact of COVID-19 on Clinical Trials
Lung Cancer COVID19 Workgroup 2021
Online.

SELECT ABSTRACTS (not exhaustive)

Matthew Smeltzer et al. The 2024 International Association for the Study of Lung Cancer (IASLC) Global Survey on Biomarker Testing: Results from Asia. PL03.03. Asia Conference on Lung Cancer, Hong Kong, China 2024. (Plenary Presentation)

Ayesha Mukhopadhyay, Walter Stevens, Amanda Young, Allison Plaxco, Judy Dudley, Kelly Pimenta, Meredith Ray, Abu Mohd Naser, Andrew Wiese, William Cooper, **Matthew Smeltzer**.
The disproportionate impact of housing discrimination on individuals living with sickle cell disease. *American Public Health Association 2024 Annual Meeting. Oral Abstract* 2142.0.

Matthew Smeltzer et al. The 2024 International Association for the Study of Lung Cancer (IASLC) Global Survey on Biomarker Testing. World Conference on Lung Cancer, San Diego, CA 2024. (Oral Presentation)

Matthew Smeltzer et al., Smoking history requirement and lung cancer (LC) screening (LCS) eligibility disparities. ASCO 2024, JCO 42, 8016-8016(2024). DOI:10.1200/JCO.2024.42.16_suppl.8016 (Oral Presentation)

Matthew Smeltzer, Olawale Akinbobola, Wei Liao, Nicholas Faris, Carrie Fehnel, Jordan Goss, Cat Shepherd, Talat Qureshi, Sara Peppers, Amanda Harris, Ashley Porter, Anita Patel, Federico Caro, Jessica Roma, Anberitha Matthews, Meredith Ray, Raymond U. Osarogiagbon. Updated Results from the Detecting Early Lung Cancer (DELUGE) in the Mississippi Delta cohort RESCUE Lung 2023 October 27-28 Poster.

Matthew P Smeltzer, Wei Liao, Nick R Faris, Carrie Fehnel, Jordan Goss, Catherine J. Shepherd, Talat Qureshi, Anberitha T Matthews, Meredith A Ray, Raymond U Osarogiagbon. Early detection of lung cancer through programmatic management of pulmonary nodules in the Mississippi Delta. October 27-28, 2023; Boston ASCO Quality Care Symposium 2023 27-Oct-23.

M. Smeltzer, W. Liao, N.R. Faris, C. Fehnel, J. Goss, C.J. Shepherd, T. Qureshi, S. Peppers, A. Harris, A. Porter, M.A. Ray, A.T. Matthews, R.U. Osarogiagbon MA02.03. Incidentally-Detected Lung Cancer in Individuals Who Smoked v Never Smoked in a US Cohort Singapore 2800 WCLC 2023 9-Sep Mini Oral

Smeltzer M, Young A, Cooper W, Wiese A, Plaxco A*, Mukhopadhyay A*, Heitzer A, Davis B, Hankins J. A Mentorship Approach to Scale-Up State-Level Implementation of Population-Level Surveillance for Sickle Cell Disease Sickle Cell Disease Association of America. Washington DC, October 2023

Smeltzer M, Mukhopadhyay A, Cooper W, Titu N. Tennessee Sickle Cell Data Collection Program Updates. Oral Panel Section, TPHA, Murfreesboro TN, Sept 2023

Plaxco AP*, Evans D, Young A, Mukhopadhyay A, Nolan V, Ray M, Cooper W, **Smeltzer M**. Accessibility of Specialty Care Providers to Sickle Cell Disease Patients in Tennessee. Poster A-248, Poster Session A, Theme: High Cost, High Need Populations, Sunday, June 25 – 3:30-4:45 p.m.

Plaxco AP*, Dudley J, Mukhopadhyay A, Hankins J, Young A, Ray M, Nolan VG, Davis R, Carroll Y, Whartenby J, **Smeltzer MP**, Cooper W. Understanding the Burden of Sickle Cell Disease in Rural and Urban Tennessee. Poster A-426, Poster Session A, Theme: Public and Population Health, Sunday, June 25

Pimenta K*, **Smeltzer M**, Mukhopadhyay A, Baird A Identifying the Global Limitations and Barriers to Telehealth: A Healthcare Provider's Perspective. The Mid-South DATA Conference 2023/April 6th , 2023.

Ayesha Mukhopadhyay*, Vikki G. Nolan, Allison P. Plaxco, Judy Dudley, Jane S. Hankins, Amanda J. Young, Meredith A. Ray, Robert Davis, Yvonne M. Carroll, Jamie D. Whartenby, Abu Mohd Naser, Kelly Pimenta, Samuel Muhith, Andrew Wiese, Andrew Heitzer, William O. Cooper, **Matthew P. Smeltzer**, Demographic associations of chronic comorbidities in sickle cell disease. Poster Session APHA, Atlanta GA, Nov 12-14 2023.

Allison Plaxco*, Judy Dudley, Ayesha Mukhopadhyay, Vikki Nolan, Jane Hankins, Amanda Young, Meredith Ray, Robert Davis, Yvonne Carroll, Jamie Whartenby, Andrew Heitzer, Andrew Wiese, William Cooper, and **Matthew P. Smeltzer**, Characterizing acute care utilization patterns among individuals with sickle cell disease in Tennessee Poster Session APHA, Atlanta GA, Nov 12-14 2023.

Plaxco AP, Evans D, Young A, Mukhopadhyay A, Nolan V, Ray M, Cooper W, **Smeltzer M**. Accessibility of Specialty Care Providers to Sickle Cell Disease Patients in Tennessee. Poster A-248, Poster Session A, Theme: High Cost, High Need Populations, Sunday, June 25 – 3:30-4:45 p.m.

Plaxco AP, Dudley J, Mukhopadhyay A, Hankins J, Young A, Ray M, Nolan VG, Davis R, Carroll Y, Whartenby J, **Smeltzer MP**, Cooper W. Understanding the Burden of Sickle Cell Disease in Rural and Urban Tennessee. Poster A-426, Poster Session A, Theme: Public and Population Health, Sunday, June 25 – 3:30-4:45 p.m.

Pimenta K, **Smeltzer M**, Mukhopadhyay A, Baird A. Identifying the Global Limitations and Barriers to Telehealth: A Healthcare Provider's Perspective. The Mid-South DATA Conference 2023/April 6th, 2023.

Smeltzer M, Faris N, Lee YS, Fehnel C, Akinbobola O, Jones C, Meadows-Taylor M, Saulsberry A, Dox H, Eubanks R, Valaulikar G, Talton D, Wolf B, Wiggins H, Sievers E, Levy P, Robbins E, Ray M, Osarogiagbon RU. Improving Overall Survival in Non-Small Cell Lung Cancer by Reducing R-Uncertain Resections With a Lymph Node Specimen Collection Kit. Abstract 1409. MA09.08. 2020 World Conference on Lung Cancer, Worldwide Virtual Event, January 28 - 31, 2021.

Smeltzer M. Tennessee Sickle Cell Disease Surveillance Program. Invited Presenation Tennessee Public Heath Association Annual Meeting. September 10, 2020.

Smeltzer M, Ray M, Faris N, Meadows M, Fehnel C, Akinbobola O, Jackson B, Foust C, McHugh L, Signore R, Robbins E, Osarogiagbon R. Outcomes from a multidisciplinary thoracic oncology conference (MTOC) versus serial care (SC) in a community healthcare system. J Clin Oncol 38, 2020 (suppl 29; abstr 55). DOI: 10.1200/JCO.2020.38.29_suppl.55

Smeltzer M , Lee YS , Faris N, Fehnel C, Houston-Harris C, Meadows-Taylor M, Ray M, Mahul A, Fullenwider J, Okun S, Spencer D, Sales E, Osarogiagbon R. Improving Quality of Pathology Reports for Resected Non-Small Cell Lung Cancer (NSCLC) in the Mid-South US. OFP01.04. 2020 North America Conference on Lung Cancer, Worldwide Virtual Event October 16-17, 2020.

Smeltzer M, Boehmer L, Kramar A, Asfeldt T, Faris N, Amorosi C, Ray M, Nolan V, Oyer R, Lathan C, Osarogiagbon R. An Optimal Care Coordination Model (OCCM) for Medicaid patients with lung cancer: Results from the beta model testing phase of a multisite initiative in the United States. 2020 ASCO Quality Care Symposium Journal of Clinical Oncology 2020 38:29_suppl, 105-105

Smeltzer M, Boehmer L, Kramar A, Asfeldt T, Faris N, Ray M, Lathan C, Osarogiagbon R. An optimal care coordination model for Medicaid patients with lung cancer: Lessons learned from the beta testing phase of a multisite initiative in the United States. Abstract e14010. American Society of Clinical Oncology 2020 Virtual Scientific Program, Chicago, IL, May 29 to May 31, 2020. *Journal of Clinical Oncology* 38, no. 15_suppl.

Smeltzer M, Ray M, Faris N, Meadows M, Fehnel C, Akinbobola C, Jackson B, Foust C, McHugh L, Signore R, Robbins E, Osarogiagbon R. Outcomes from a multidisciplinary thoracic oncology conference (MTOC) versus serial care (SC) in a community healthcare system. 2020 ASCO Quality Care Symposium Journal of Clinical Oncology 2020 38:29_suppl, 55-55

Smeltzer M, Wynes M, Lantuejoul S, Soo RA, Dalurzo L, Felip E, Hollenbeck G, Howell K, Kerr K, Kim E, Mathias C, Postmus P, Powell C, Ramalingam S, Richeimer K, Taylor M, Tsuboi M, Varella-Garcia M, Wistuba I, Wood K, Scagliotti G, Hirsch F. Comparing Regional Results from the IASLC Global Survey on Molecular Testing in Lung Cancer. Oral Abstract Session Oct 11, 2019: Room 1, 14:00 - 15:4.

Smeltzer M, Wynes M, Taylor M, Richeimer K, Wood K, Howell K, Dalurzo M, Felip E, Kerr K, Kim E, Lantuejoul S, Mathias C, Postmus P, Powell C, Ramalingam S, Soo R, Tsuboi M, Wistuba I, Varella-Garcia M, Scagliotti G, Hirsch FR. The International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung Cancer. MA21. Abstract 1198. 20th World Conference on Lung Cancer 2019.

Smeltzer M, Asfeldt T, Faris N, Kramar A, Amorosi C, Nolan V, Ray M, Dawkins M, Nalan MC, Stevens W, Lucas L, Oyer R, Lathan C, Osarogiagbon R. Testing an Optimal Care Coordination Model (OCCM) for Lung Cancer in a Multi-Site Study. MA19. Abstract 2659. 20th World Conference on Lung Cancer 2019. (Accepted)

Smeltzer MP, Stevens W, Faris NR, Kethireddy J, Meadows MB, Ray MA, Epperson A, Adams K, Fulford A, Wagh A, Machin J, Tonkin K, Optican R, Wright J, Robbins ET, Osarogiagbon RU. Lung cancer diagnosed by an incidental lung nodule program or lung cancer screening. Abstract 8546. ASCO Annual Meeting 2019; Chicago, IL.

Osarogiagbon RU, Faris NR, **Smeltzer M,** Ray M, Ward KD, Rugless F, Jackson BM, Meadows MB*, Berryman C, Fehnel C, Houston-Harris C. 2019. Prospective comparative effectiveness trial of multidisciplinary lung cancer (LC) care. *Journal of Clinical Oncology*; 37(15) 6549-6549.

Taylor M*, **Smeltzer M**, Faris N, Ray M, Fehnel C, Houston-Harris C, Akinbobola O*, Ojeabulu P, Osarogiagbon R. 2019 Racial Disparities in Long-Term Survival After Surgical Resection in the US. *Journal of Thoracic Oncology*;14(10) S602-S602.

Ray M, Faris NR, Derrick A, **Smeltzer M**, Osarogiagbon RU. 2019. The relative impact of patient and institutional rurality on lung cancer disparities. *Journal of Clinical Oncology*; 37(15) e20052-e20052.

M. Smeltzer, N. Faris, J. Kethireddy, M. Meadows, M. Nalan, M. Ray, A. Epperson, D. Richards, K. Adams, A. Fulford, A. Wagh, J. Machin, K. Tonkin, R. Optican, J. Wright, E. Robbins, R. Osarogiagbon. Comparing Lung Cancer Diagnosed by Low Dose CT (LDCT), Incidental Lung Nodule Program (ILNP), and non-program based detection. 19th World Conference on Lung Cancer 2018. P1.11-11

A. Marbaugh, T. Asfeldt, R. Oyer, C. Lathan, **M. Smeltzer**, V. Nolan, M. Ray, N. Faris, M. Nalan, W. Stevens, A. Kramar, L. Lucas, R. Osarogiagbon. Creating an optimal care coordination model to improve multidisciplinary care for lung cancer patients on Medicaid. 19th World Conference on Lung Cancer 2018. P1.15-21

M. Smeltzer, N. Faris, M. Ray, C. Fehnel, O. Akinbobola, C. Houston-Harris, P. Ojeabulu, Y. Lee, E. Owen, R. Eubanks, H. Dox, D. Talton, H. Wiggins, B. Wolf, P. Levy, E. Robbins, R. Osarogiagbon. A population-based validation study of the proposed 'R-Factor' classification in a lung cancer endemic region of the US. 19th World Conference on Lung Cancer 2018. P1.16-46

M. Ray, **M. Smeltzer**, N. Faris, Y. Lee, C. Fehnel, C. Houston-Harris, O. Akinbobola, P. Ojeabulu, E. Owen, R. Eubanks, H. Dox, D. Talton, G. Valaulikar, H. Wiggins, B. Wolf, P. Levy, E. Robbins, R. Osarogiagbon. Pattern and Survival impact of neoadjuvant treatment of non-small cell lung cancer (NSCLC) in a prospective lung resection cohort. 19th World Conference on Lung Cancer 2018. P1.17-11

Y. Lee*, **M. Smeltzer**, M. Ray, N. Faris, C. Fehnel, C. Houston-Harris, O. Akinbobola, P. Ojeabulu, E. Owen, R. Eubanks, H. Dox, D. Talton, H. Wiggins, B. Wolf, P. Levy, E. Robbins, R. Osarogiagbon. Survival implications and factors associated with the anatomic level of incomplete non-small cell lung cancer (NSCLC) resection. 19th World Conference on Lung Cancer 2018. P2.16-32

M. Ray, **M. Smeltzer**, N. Faris, Y. Lee, C. Fehnel, C. Houston-Harris, O. Akinbobola, P. Ojeabulu, E. Owen, R. Eubanks, H. Dox, D. Talton, G. Valaulikar, H. Wiggins, B. Wolf, P. Levy, E. Robbins, R. Osarogiagbon. Characteristics of preoperative N staging in patients with optimal pathologic N staging of non-small cell lung cancer (NSCLC). P2.16-38

N. Faris, Y. Lee, **M. Smeltzer**, M. Ray, C. Fehnel, C. Houston-Harris, O. Akinbobola, P. Ojeabulu, E. Owen, R. Eubanks, H. Dox, D. Talton, G. Valaulikar, H. Wiggins, B. Wolf, P. Levy, E. Robbins, R. Osarogiagbon. Characteristics and survival of resected stage IV non-small cell lung cancer (NSCLC) in the mid-south quality of surgical resection cohort. 19th World Conference on Lung Cancer 2018. MA25.05

Osarogiagbon RU, **Smeltzer MP**, Faris NR, Ray MA, Fehnel C, Houston-Harris C, Ojeabulu P, Akinbobola O, Wiggins HL, Talton D, Owen Ed, Deese L, Eubanks R, Wolf BA, Robbins ET. Pragmatic Study of a Lymph Node (LN) Collection Kit for Non-Small Cell Lung Cancer (NSCLC) Resection. Abstract #224733. ASCO; June 1-5, 2018; Chicago, IL.

Smeltzer MP, Ray MA, Faris NR, Meadows MB, Fehnel C, Houston-Harris C, Ojeabulu P, Akinbobola O, Lee YS, Wiggins HL, Talton D, Owen E, Deese L, Eubanks R, Wolf BA, Robbins ET, Osarogiagbon RU. Survival in the Population-based Mid-South Quality of Surgical Resection (MSQSR) Cohort. Abstract #229193. ASCO; June 1-5, 2018; Chicago, IL.

Ray MA, **Smeltzer MP**, Faris NR, Fehnel C, Houston-Harris C, Ojeabulu P, Akinbobola O, Wiggins HL, Talton D, Owen E, Deese L, Eubanks R, Wolf BA, Robbins ET, Osarogiagbon RU. Implementing improved pathologic nodal (pN) staging during non-small cell lung cancer (NSCLC) resection: a population-based study. Abstract #225079. ASCO; June 1-5, 2018; Chicago, IL.

Ward KD, Chen W, **Smeltzer MP**, Meadows MB, Faris NR, Berryman C, Jackson BM, Rugless F, Ray MA, Osarogiagbon RU. Patient-Reported Satisfaction with Multidisciplinary (MD) v Serial Care (SC) for Lung Cancer. Abstract #223713 ASCO; June 1-5, 2018; Chicago, IL.

Smeltzer MP, Lee YS, Faris NR, Ray MA, Fehnel C, Houston-Harris C, Ojeabulu P, Akinbobola O, Deese L, Owen E, Wolf B, Wiggins HL, Mutrie V, Sachdev V, Levy P, Signore RS, Robbins ET, Osarogiagbon RU. Thoroughness of staging and the outcomes of surgical resection in potentially curable non-small cell lung cancer (NSCLC). 18th World Conference on Lung Cancer 2017. OA 15 - Diagnostic Radiology, Staging and Screening for Lung Cancer II. Oct 18, 2017.

Ward KD, **Smeltzer MP**, Rugless FE, Faris NR, Ray MA, Jackson B, Foust C, Patel A, Meadows M, Boateng N, Roark K, Crossley F, Oliver G, McHugh L, Hastings W, Osborne O, Osborne J, Ill T, Ill M, Signore RS, Fox R, Robbins ET, Osarogiagbon RU. Prospective Comparative Evaluation of Patient and Caregiver Perspectives on a Multidisciplinary Model of Lung Cancer Care . 18th World Conference on Lung Cancer 2017, MA 04 - Advocacy: Listen to the Patients. Oct 16, 2017.

Smeltzer MP, Rugless FE, Lee HK, Ward KD, Faris N, Ray MA, Meadows M, Jiang B, Jackson B, Foust C, Patel A, Boateng N, Kedia S, Roark K, Houston-Harris C, Fehnel C, Signore RS, Fox R, Robbins ET, Li J, Osarogiagbon RU. Prospective Evaluation of Multidisciplinary Lung Cancer Care: Timeliness, Thoroughness, and Patient/Caregiver Perspectives. IASLC 2017 Chicago Multidisciplinary Symposium in Thoracic Oncology Oral 4B.03. September 15, 2017.

Smeltzer MP, Meadows MB, Faris NR, Stewart FE, Ray M, Lee YS, Boateng N, Foust C, Jackson B, Patel A, Fehnel C, Houston-Harris C, Signore RS, Robbins ET, Osarogiagbon RU. Increased Use of PET-CT, Invasive Staging, and Surgical Resection with a Multidisciplinary Lung Cancer Care Model: Effectiveness Endpoints from an Implementation Study. Annals of Epidemiology, 2017 ACE Meeting Abstract PS12.

Smeltzer M, Faris N, Stewart F, Ray M, Boateng N, Meadows M, Foust C, Jackson B, Patel A, Fehnel C, Houston-Harris S, Signore R, Robbins E, Osarogiagbon R. Staging in multidisciplinary (MDC) v serial care (SC) lung cancer (LCa) patients (Pts). J Clin Oncol 35, 2017 (suppl; abstr e20079)

Ward K, Boateng N, Stewart F, **Smeltzer M**, Jackson B, Foust C, Faris N, Ray M, Osarogiagbon R. Satisfaction among lung cancer (LCa) patients (pts) in multidisciplinary (MDC) vs. serial care (SC) settings. J Clin Oncol 35, 2017 (suppl; abstr e18254)

Ray M, Faris N, Stewart F, **Smeltzer M**, Boateng N, Meadows M, Foust C, Jackson B, Patel A, Fehnel C, Houston-Harris C, Signore R, Robbins E, Osarogiagbon R. Treatment of lung cancer patients in multidisciplinary (MDC) and serial care (SC) clinics. J Clin Oncol 35, 2017 (suppl; abstr 8522).

Smeltzer M, Klesges L, Lee YS, Faris N, Fehnel C, Houston-Harris C, Ray M, Robbins E, Osarogiagbon R. Reach and Adoption of a Surgical Intervention To Improve Pathologic Nodal Staging Across Healthcare Systems within the US. 2016 Mid-South IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology (Abstract 111).

Smeltzer M, Lee YS, Robbins E, Faris N, Mutrie C, Ray M, Signore S, Fehnel C, Houston-Harris C, Meadows M, Osarogiagbon R. Predictors of Post-Operative Mortality in Non-Small Cell Lung Cancer (NSCLC) in a High Mortality Region of the US. 17th World Conference on Lung Cancer, December 4-8, 2016 (Abstract 4447).

Smeltzer M, Faris N, Fehnel C, Houston-Harris C, Ray M, Lee YS, Meadows M, Robbins E, Signore S, Mutrie C, Osarogiagbon R. Validation of the IASLC 8th Edition (8E) TNM Classification for Non-Small Cell Lung Cancer by the Quality of Surgical Resection in a US Cohort. 17th World Conference on Lung Cancer, December 4-8, 2016 (Abstract 6237).

Smeltzer M, Faris N, Fehnel C, Houston-Harris C, Ray M, Lee YS, Meadows M, Signore S Mutrie C, Robbins E, Osarogiagbon R. The Impact of IASLC 8th Edition Updates for T-Classification for Lung Cancer in a US

Population-Based Surgical Resection Cohort. 17th World Conference on Lung Cancer, December 4-8, 2016 (Abstract 6241).

Smeltzer M, Klesges L, Lee YS, Faris N, Ray M, Fehnel C, Houston-Harris C, Signore S, Robbins E, Osarogiagbon R. The Reach and Adoption of a Surgical Intervention for Lung Cancer Across Healthcare Systems within the US Mid-South Region. 9th Annual Conference on the Science of Dissemination and Implementation (December 2016).

Smeltzer M, Stewart F, Faris N, Foust C, Jackson B, Roark K, McHugh L, Signore R, Oliver G, Robbins E, Klesges L, Osarogiagbon R; The reach of a community-based multidisciplinary (MD) thoracic oncology program (P). J Clin Oncol 34, 2016 (suppl; abstr e18045)

Osarogiagbon R, Lin CC**, Smeltzer M**, Jemal A. Overall survival (OS) implications of institutional disparities in non-small cell lung cancer (NSCLC) pathologic nodal (pN) staging practice in the National cancer data base (NCDB). J Clin Oncol 34, 2016 (suppl; abstr 6554)

Jemal A, Lin CC, **Smeltzer M**, Osarogiagbon R. Non-examination of lymph nodes (LN) and overall survival (OS) in non-small cell lung cancer (NSCLC) patients. J Clin Oncol 34, 2016 (suppl; abstr 8547)

Lin CC, **Smeltzer M**, Jemal A, Osarogiagbon R. Risk-adjusted margin positivity (RAMP) rate as a surgical quality metric for non-small-cell lung cancer (NSCLC). J Clin Oncol 34, 2016 (suppl; abstr 8551)

Stewart F, **Smeltzer M**, Faris N, Foust C, Jackson B, Roark K, McHugh L, Signore S, Oliver G, Robbins E, Klesges L, Osarogiagbon R. Variance in Multidisciplinary (MultiD) recommendations in a conference only vs co-located clinic model. J Clin Oncol 34, 2016 (suppl; abstr e18039)

Faris N, Lu F, **Smeltzer M**, Fehnel C, Chakraborty N, Houston-Harris C, Signore R, Robbins E, Osarogiagbon R. Use and performance of mediastinoscopy before surgery for non-small cell lung cancer (NSCLC) in the Mid-South region of the United States (US). J Clin Oncol 34, 2016 (suppl; abstr 8543)

Smeltzer MP, Lin CC, Yu X, Jemal A, and Osarogiagbon RU. Survival Impact of Post-Operative Therapy Modalities After Incomplete and Complete Surgical Resection for Non-Small Cell Lung Cancer in the US. 16th World Conference on Lung Cancer, September 6-9, 2015 (ORAL 20.07).

Smeltzer, Rugless, Faris, Yu, Eke, Relyea, Fehnel, Chakraborty, Houston-Harris, Lu, Spencer, Berry, Sales, Finch-Cruz, and Osarogiagbon. Trends in Accuracy and Comprehensiveness of Pathology Reports of Resected Non-small Cell Lung Cancer (NSCLC) in a High Mortality Area of the US. 16th World Conference on Lung Cancer, September 6-9, 2015 (P1.12-001).

X. Yu, N. Faris, R. Eke, **M.P. Smeltzer**, G. Relyea, F.E. Rugless, C. Fehnel, N. Chakraborty, C. Houston-Harris, F. Lu, E.T. Robbins, R.S. Signore, L. McHugh, B. Wolf, C. Mutrie, L. Deese, P. Levy, E. Crocker, L. Wiggins, R.U. Osarogiagbon. Impact of Attainment of the American College of Surgeons Commission on Cancer Quality Measure on Patient Survival After Lung Cancer Resection. 16th World Conference on Lung Cancer, September 6-9, 2015 (MINI06.04).

C.C. Lin, **M.P. Smeltzer**, X. Yu, R.U. Osarogiagbon, A. Jemal. Risk-Adjusted Margin Positivity (RAMP) Rate as a Surgical Quality Metric for Non-Small-Cell Lung Cancer in the US National Cancer Data Base (NCDB). 16th World Conference on Lung Cancer, September 6-9, 2015 (MINI20.02).

N. Faris, **M.P. Smeltzer**, C. Adair, A. Berry, X. Yu, L. McHugh, R.U. Osarogiagbon - The Survival Impact of Missed Lymph Node Metastasis in Surgically Resected Non-Small Cell Lung Cancer (NSCLC). 16th World Conference on Lung Cancer, September 6-9, 2015 (MINI20.03).

X. Yu, E.T. Robbins, N. Faris, R.S. Signore, L. McHugh, R. Eke, **M.P. Smeltzer**, G. Relyea, C. Fehnel, N. Chakraborty, C. Houston-Harris, F. Lu, B. Wolf, C. Mutrie, L. Deese, E. Crocker, L. Wiggins, P. Levy, R.U. Osarogiagbon Evolution in the Surgical Care of Non-Small Cell Lung Cancer (NSCLC) Patients in the Mid-South Quality of Surgical Resection (MS-QSR) Cohort. 16th World Conference on Lung Cancer, September 6-9, 2015 (ORAL30.01).

N. Faris, X. Yu, R. Eke, **M.P. Smeltzer**, G. Relyea, F.E. Rugless, C. Fehnel, N. Chakraborty, C. Houston-Harris, F. Lu, E.T. Robbins, R.S. Signore, L. McHugh, B. Wolf, C. Mutrie, L. Deese, P. Levy, E. Crocker, L. Wiggins, R.U. Osarogiagbon. Impact of Attainment of National Comprehensive Cancer Network (NCCN) Quality Parameters on Patient Survival after Resection of Lung Cancer. 16th World Conference on Lung Cancer, September 6-9, 2015 (ORAL34.02).

R.U. Osarogiagbon, G. Relyea, N. Faris, X. Yu, R. Eke, **M.P. Smeltzer**, F.E. Rugless, C. Fehnel, N. Chakraborty, C. Houston-Harris, F. Lu, R.S. Signore, L. McHugh, L. Deese, P. Levy, E. Crocker, L. Wiggins, C. Mutrie, B. Wolf, E.T. Robbins. Impact of Surgeons' Attainment of Quality Resection Parameters on Non-Small-Cell Lung Cancer (NSCLC) Patients' Survival. 16th World Conference on Lung Cancer, September 6-9, 2015 (ORAL34.06).

R.U. Osarogiagbon, C.C. Lin, **M.P. Smeltzer**, A. Jemal- Prevalence, Prognostic Implications and Survival Modulators of Incompletely Resected Non-Small Cell Lung Cancer (NSCLC) in the US. 16th World Conference on Lung Cancer, September 6-9, 2015. (ORAL34.07)

Smeltzer MP, Nolan V, Nottage K, Wang W, Gurney J, and Hankins J. Prevalence of sickle cell trait and sickle cell disease among African American live births in Shelby Co., TN. Presentation at the American Public Health Association Annual Meeting. November 2013.

Smeltzer MP, Aygun B, Nolan V, Davis B, Wang W, and Hankins J. Greater Distance from a Sickle Cell Center Does Not Compromise Routine Healthcare Management. Presented at the Global Sickle Cell Disease Network Conference, March 2012.

COMMITTEE AND ADMINISTRATIVE SERVICE

University of Memphis

Chair- Assessment and Institutional Effectiveness Committee, School of Public Health, University of Memphis. 2021-Present

Chair- Epidemiology, Biostatistics, and Environmental Health (EBE) Colloquium 2024-Present

Chair- Admissions Committee, PhD in Epidemiology and Biostatistics, University of Memphis. 2021-2024

Comprehensive Examination Committee, PhD in Epidemiology and Biostatistics, University of Memphis. 2022-Present

Admissions Committee, Master in Public Health, University of Memphis. 2015-2019

Admissions Committee, PhD in Epidemiology, University of Memphis. 2018-2020

External Committees

Board Member- Rescue Lung Society 2024-

Chair- Communications Committee- International Association for the Study of Lung Cancer (IASLC), 2025-2027

Chair- IASLC Staging and Prognostic Factors Group- Methodology Committee, 2024-

Co-Chair- Communications Committee- International Association for the Study of Lung Cancer (IASLC), 2023-2025

Communications Committee- International Association for the Study of Lung Cancer (IASLC), 2019-

IASLC Staging and Prognostic Factors Group- Methodology Committee, 2024

Chair- National Sickle Cell Data Collection (SCDC) Data and Methodology Committee 2024

Expert Panelist- IASLC initiative: *Ensuring Broader Representation of Women in Thoracic Oncology Clinical Trials*.

Publications Committee- International Association for the Study of Lung Cancer (IASLC), 2017-2019

Steering Committee- SCCRIP: Lifetime Cohort Study for Sickle Cell Disease (St. Jude Children's Res. Hosp.)

National Needs Assessment Committee- NHLBI Sickle Cell Disease Implementation Consortium (SCDIC)

American College of Epidemiology, Associate Members Leadership Committee, 2014-2016

Judge for 2017 Graduate Research Symposium, University of Memphis

MEMBERSHIPS

Rescue Lung Society
American Statistical Association (PStat, inactive)
American Society of Clinical Oncology
International Association for the Study of Lung Cancer
SAS Users Group, Memphis

REVIEWER

Editorial Board Member- Translational Lung Cancer Research, 2021-
Review Team Member- Journal of Thoracic Oncology, 2018-
Ad hoc reviewer- JTO-CCR, 2024-
Ad hoc reviewer- JAMA Internal Medicine, 2025-
Ad hoc reviewer- Pediatric Blood and Cancer, 2013-
Ad hoc reviewer- American Journal of Health Behavior, 2013-
National Undergraduate Research Conference 2017
World Conference on Lung Cancer- Abstracts 2023-

RESEARCH SUPPORT

Data Coordinating Center for Pathologic Response as an Early Clinical Endpoint (PRECENT)
MPI: Smeltzer, Ray
5/1/2025 – 5/1/2029
Source: International Assoc. for the Study of Lung Cancer
Role: Multiple Principal Investigator
Amount: $800,226

Tennessee Public Health Surveillance Program for Sickle Cell Disease
NU58DD000035 (PI: Smeltzer)
09/30/2023 - 09/29/2028
Source: US Centers for Disease Control and Prevention
Role: Principal Investigator
CDC-RFA-DD-23-0002 Sickle Cell Data Collection Program
Amount: $476,610 per year

Predoctoral Research Training Program in Global Hematology and Public Health
PI: Smeltzer
8/1/2025 - 7/31/2027 (renewable annually)
Source: St. Jude Children's Research Hospital
Role: Principal Investigator
Amount: $35,000 per year

Using Real-World Data to Evaluate Modern Pharmacotherapy Treatment Regimens and Prophylaxis for Reducing Infections in Sickle Cell Disease
PI. Wiese A
1R01HL183867-01A1
07/2026 - 06/2031
Role: Site Principal Investigator
Amount: $3,980,784

Predicting Progression of Chronic Kidney Disease in Sickle Cell Anemia Using Machine Learning Models (PREMIER)
1R01HL159376-01 (PI: Kenneth Ataga, MD)
09/10/2021 – 09/09/2026
Source: National Heart Lung and Blood Institute (NIH)
Role: Site Principal Investigator
Amount: $705,287

The 2024 International Association for the Study of Lung Cancer (IASLC) Global Survey on Evolving Trends in Biomarker Testing for Lung Cancer.
PI: Smeltzer
10/24/23 – 12/31/2024
Source: IASLC Partners for Thoracic Oncology
Role: Principal Investigator
Amount: $78,639

IASLC Squamous Cell Carcinoma Grading Project- Analytic Component
PI: Smeltzer
08/01/2023 – 12/31/2024

Source: International Assoc. for the Study of Lung Cancer
Role: Principal Investigator
Amount: $17,145

Improving N1 lymph node examination in a high US lung cancer mortality region.
2-R01CA172253 (PI: Raymond Osarogiagbon, MBBS).
08/01/2018-7/31/2023
Source: National Cancer Institute (NIH)
Role: Site Principal Investigator
Amount: $2,500,000

Tennessee Sickle Cell Disease Surveillance Program– Core Component
NU58DD000019-01 (PI: Smeltzer (contact)/Hankins/Davis/Cooper)
09/30/2020 – 09/29/2023
Source: US Centers for Disease Control and Prevention
Role: Contact Principal Investigator (MPI)
Amount: $748,212

Tennessee Sickle Cell Disease Surveillance Program– Optional Component
NU58DD000019-02 (PI: Smeltzer (contact)/Hankins/Davis/Cooper)
09/30/2021 – 09/29/2023
Source: US Centers for Disease Control and Prevention
Role: Contact Principal Investigator (MPI)
Amount: $475,000

ReHASH: Re-aiming at Hydroxyurea Adherence for Sickle Cell with mHealth
U01HL133996-01 (PI: Jane Hankins, MD, M.S)
07/01/2016-06/30/2022
Source: National Heart Lung and Blood Institute (NIH)
Role: Site Principal Investigator
Amount: $4,300,000

Tennessee Sickle Cell Disease Surveillance Program – CARES Act Supplement
NU58DD000019-02 (PI: Smeltzer (contact)/Hankins/Davis/Cooper)
09/30/2021 – 09/29/2022
Source: Centers for Disease Control and Prevention
Role: Contact Principal Investigator (MPI)
Amount: $130,088

Analysis of Global Survey on COVID-19 and Clinical Trials
PI: Smeltzer
03/01/2021 – 02/28/2022
Source: International Assoc. for the Study of Lung Cancer
Role: Principal Investigator
Amount: $20,000

Analysis of Global Survey on Molecular Testing in Lung Cancer
PI: Smeltzer
05/01/2019 – 04/30/2020
International Assoc. for the Study of Lung Cancer
Role: Principal Investigator

Amount: $19,000

Centers for Disease Control and Prevention DD19-1906
09/15/2019 – 09/14/2020
(PI: Davis/Hankins/Smeltzer/Cooper)
Building Capacity for the Tennessee Sickle Cell Disease Surveillance Program
Role: Multiple Principal Investigator
Amount: $100,000

Epidemiology, Biostatistics, and Data Coordinating Center (EBDCC)
PI: Smeltzer
07/01/2017 - 8/31/2019
Creating an Optimal Care Coordination Model for Lung Cancer Patients on Medicaid
Association of Community Cancer Centers
Role: Principal Investigator
Amount: $320,000

Dissemination of a Corrective Intervention to Improve Lymph Node Examination in Resected Lung Cancer
R01CA172253 (PI: Raymond Osarogiagbon, MBBS)
04/01/2013-07/31/2018
Source: National Cancer Institute (NIH)
Role: Co-Investigator
Amount: $2,500,000

ECOSYSTENN: Education and Clinical Outcomes in Youth with Sickle Cell in Tennessee
R073223660 (PI: Robert Davis, MD)
11/01/2016-10/01/2021
Source: Memphis Research Consortium
Role: Site Principal Investigator
Amount: $100,000

Building a multidisciplinary bridge across the quality chasm in thoracic oncology.
IH-1304-6147. (PI: Raymond Osarogiagbon, MBBS).
02/03/2014 – 08/02/2017
Source: Patient Centered Outcomes Research Insitute (PCORI)
Role: Co-Investigator
Amount: $1,655,292

Epidemiology and Biostatistics Support for Baptist Lung Multidisciplinary (lung MD) Program
PI: Matthew Smeltzer, PhD
03/15/2015 - 08/31/2017
Source: Baptist Cancer Center
Role: Principal Investigator
Amount: $118,925

Neutrophil Response to Tissue Templates in Vitro: Implant Implications
R15 EB022345-01A1 (PI: Gary Bowlin, PhD)
04/17/2017 - 04/17/2019
National Institutes of Health (NIH)

Role: Co-Investigator
Amount: $427,409

Designing Drug-eluting Regeneration Templates to Down-regulate Neutrophil Extracellular Traps
R21 EB024131-01 (PI: Gary Bowlin PhD)
04/24/2017 - 04/24/2019
Source: National Institutes of Health (NIH)
Role: Co-Investigator
Amount: $200,000

To serve as the Data Coordinating Center, SCATE (Multicenter International RCT of Hydroxyurea Use in Pediatric Sickle Cell Disease).
R01HL098239-03 (PI: Russell Ware, MD, Ph.D., James Boyett, Ph.D.)
9/01/2010 – 08/31/2013
Source: National Heart Lung and Blood Institute (NIH)
Role: Biostatistician

To develop, implement, and validate in patients with hepatic iron overload an ultra short echo time MRI technique - R2*-UTE .
R01DK088988-03 (PI: Claudia Hillenbrand, Ph.D., Jane Hankins, MD, M.S.)
08/01/2010 – 04/30/2014
Source: National Heart Lung and Blood Institute (NIH)
Role: Biostatistician

Sickle Cell Treatment Demonstration Program: To enhance the prevention and treatment of sickle cell disease through coordination of service delivery, genetic counseling and testing, bundling of technical services, training of health professionals, and continuity of care for individuals with sickle cell disease.
HRSA 10-094 – 1 U1EMC19331-01-00 (PI: Jane Hankins, MD, M.S)
09/01/2010 - 08/31/2014
Source: Health Resource and Service Adminstration
Role: Biostatistician